<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2105</journal-id><journal-id journal-id-type="pmc-domain">cancers</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10969110</article-id><article-id pub-id-type="pmcid-ver">PMC10969110.1</article-id><article-id pub-id-type="pmcaid">10969110</article-id><article-id pub-id-type="pmcaiid">10969110</article-id><article-id pub-id-type="pmid">38539525</article-id><article-id pub-id-type="doi">10.3390/cancers16061191</article-id><article-id pub-id-type="publisher-id">cancers-16-01191</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0414-1607</contrib-id><name name-style="western"><surname>Gale&#537;</surname><given-names initials="LN">Lauren&#539;ia Nicoleta</given-names></name><xref rid="af1-cancers-16-01191" ref-type="aff">1</xref><xref rid="af2-cancers-16-01191" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>P&#259;un</surname><given-names initials="MA">Mihai-Andrei</given-names></name><xref rid="af3-cancers-16-01191" ref-type="aff">3</xref><xref rid="c1-cancers-16-01191" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anghel</surname><given-names initials="RM">Rodica Maricela</given-names></name><xref rid="af1-cancers-16-01191" ref-type="aff">1</xref><xref rid="af3-cancers-16-01191" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9566-7067</contrib-id><name name-style="western"><surname>Trif&#259;nescu</surname><given-names initials="OG">Oana Gabriela</given-names></name><xref rid="af1-cancers-16-01191" ref-type="aff">1</xref><xref rid="af3-cancers-16-01191" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Mroczko</surname><given-names initials="B">Barbara</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Gudowska-Sawczuk</surname><given-names initials="M">Monika</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cancers-16-01191"><label>1</label>Department of Oncology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania; <email>laurentia.gales@umfcd.ro</email> (L.N.G.); <email>rodica.anghel@umfcd.ro</email> (R.M.A.); <email>oana.trifanescu@umfcd.ro</email> (O.G.T.)</aff><aff id="af2-cancers-16-01191"><label>2</label>Department of Medical Oncology II, Prof. Dr. Al. Trestioreanu Institute of Oncology, 022328 Bucharest, Romania</aff><aff id="af3-cancers-16-01191"><label>3</label>Department of Radiotherapy II, Prof. Dr. Al. Trestioreanu Institute of Oncology, 022328 Bucharest, Romania</aff><author-notes><corresp id="c1-cancers-16-01191"><label>*</label>Correspondence: <email>mihai-andrei.paun@rez.umfcd.ro</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><volume>16</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">458650</issue-id><elocation-id>1191</elocation-id><history><date date-type="received"><day>15</day><month>2</month><year>2024</year></date><date date-type="rev-recd"><day>08</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-09 19:26:32.620"><day>09</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cancers-16-01191.pdf"/><abstract><sec><title>Simple Summary</title><p>This article is intended to serve as a roadmap for scientists, steering them toward fruitful avenues of investigation. Moreover, the review makes a compelling argument for the implementation of universal cancer screening and multi-cancer early detection screening. It synthesizes evidence supporting the efficacy of such screenings, emphasizing their potential to detect various cancers at early, more treatable stages. By presenting a well-reasoned case, the review contributes to the discourse on the importance of widespread screening, urging healthcare providers and policymakers to consider its adoption for improved cancer detection and outcomes.</p></sec><sec><title>Abstract</title><p>Cancer continues to pose a considerable challenge to global health. In the search for innovative strategies to combat this complex enemy, the concept of universal cancer screening has emerged as a promising avenue for early detection and prevention. In contrast to targeted approaches that focus on specific populations or high-risk individuals, universal screening seeks to cast a wide net to detect incipient malignancies in different demographic groups. This paradigm shift in cancer care underscores the importance of comprehensive screening programs that go beyond conventional boundaries. As our understanding of the complex molecular and genetic basis of cancer deepens, the need to develop comprehensive screening methods becomes increasingly apparent. In this article, we look at the rationale and potential benefits of universal cancer screening.</p></sec></abstract><kwd-group><kwd>universal cancer screening</kwd><kwd>multi-cancer early detection</kwd><kwd>biomarker</kwd><kwd>cancer screening</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-16-01191"><title>1. Introduction</title><p>In 2020, the World Health Organization (WHO) statistics showed that cancer exacts an alarming toll, one in six deaths per year worldwide, with an alarming increase in overall mortality globally [<xref rid="B1-cancers-16-01191" ref-type="bibr">1</xref>,<xref rid="B2-cancers-16-01191" ref-type="bibr">2</xref>,<xref rid="B3-cancers-16-01191" ref-type="bibr">3</xref>].</p><p>Cancer mortality can be prevented through cancer screening programs, which have a considerable impact on reducing cancer-specific mortality by selecting pre-symptomatic cases and driving more extensive diagnostic procedures and finally prompt treatment. For instance, breast cancer mortality in the United States declined by 53.2% between 1975 and 2014, with similar trends observed in Europe, which is attributed to both screening and improved treatments [<xref rid="B4-cancers-16-01191" ref-type="bibr">4</xref>,<xref rid="B5-cancers-16-01191" ref-type="bibr">5</xref>,<xref rid="B6-cancers-16-01191" ref-type="bibr">6</xref>]. There is a need to avoid late detection, which is when cancer is diagnosed when it has already progressed beyond any potential curative options, or metastasized, where it is most often fatal, which in an estimated 15% of cases could have been avoided by early disease detection.</p><p>Among the countries with the highest per capita healthcare spending, cancer screening recommendations are relatively consistent, including breast, cervical, colorectal, prostate, skin, and lung cancer screening. However, differences in healthcare utilization exist between countries (and even within them), with a particular impact on cancer screening recommendations [<xref rid="B4-cancers-16-01191" ref-type="bibr">4</xref>,<xref rid="B7-cancers-16-01191" ref-type="bibr">7</xref>]. As such, there is a lack of universal consensus on which cancers should be screened for in the general population, with important malignancies left unchecked. For instance, cancers of the lung, pancreas, esophagus, stomach, and ovary are most often diagnosed in the metastatic setting, with a lack of population-based methods for screening, which is the case for up to 60% of cancer-related deaths where nationwide strategies for screening do not exist [<xref rid="B8-cancers-16-01191" ref-type="bibr">8</xref>,<xref rid="B9-cancers-16-01191" ref-type="bibr">9</xref>,<xref rid="B10-cancers-16-01191" ref-type="bibr">10</xref>].</p><p>Current screening methods have increased survival rates, but they also have some drawbacks, including the risk of overdiagnosis, false-positive results, exposure to radiation, invasiveness leading to a decrease in patience compliance, and lack of support from the general public to undergo these investigations [<xref rid="B10-cancers-16-01191" ref-type="bibr">10</xref>,<xref rid="B11-cancers-16-01191" ref-type="bibr">11</xref>,<xref rid="B12-cancers-16-01191" ref-type="bibr">12</xref>,<xref rid="B13-cancers-16-01191" ref-type="bibr">13</xref>,<xref rid="B14-cancers-16-01191" ref-type="bibr">14</xref>,<xref rid="B15-cancers-16-01191" ref-type="bibr">15</xref>,<xref rid="B16-cancers-16-01191" ref-type="bibr">16</xref>].</p><p>Furthermore, the current perspective on cancer screening might be conceptually inexact, as detection relies on &#8220;one organ at a time&#8221; intervention (<xref rid="cancers-16-01191-f001" ref-type="fig">Figure 1</xref>). Thus, most screening strategies are ineffective due to the high cost of a method designed only for one malignancy, thus excluding the potential diagnosis of other cancers that the patient might be suffering from. In contrast, universal cancer screening is a concept that predicts a future where detection is directed at multiple organs and multiple tumor types simultaneously with a single, potentially non-invasive method. So far, myriad multi-cancer early detection (MCED) methods have been proposed, gathering interest from clinicians to improve cancer detection and outcomes [<xref rid="B7-cancers-16-01191" ref-type="bibr">7</xref>,<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>,<xref rid="B18-cancers-16-01191" ref-type="bibr">18</xref>].</p><p>In this article, our goal is to provide insights on new developments in MCED biomarker research by sharing the latest results and directions that bring us closer to universal cancer screening, a concept that envisions testing persons from the general population to detect early cancers, no matter which type or site, in their pre-symptomatic phase, with a single, cost-effective, minimally invasive test.</p></sec><sec id="sec2-cancers-16-01191"><title>2. Status Quo of Cancer Screening</title><p>Before we present the updates in screening biomarker research, we want to briefly present the current materials and methods for cancer screening. It is important to note that there is still a long way to go until consensus is reached over the targeted population (risk categories, age, frequency of testing) and that these tests have different categories of recommendation (<xref rid="cancers-16-01191-t001" ref-type="table">Table 1</xref>).</p><sec id="sec2dot1-cancers-16-01191"><title>2.1. Colorectal Cancer</title><p>Colorectal cancer benefits from some of the best screening tools available, including stool tests and colonoscopies.</p><p>Stool-based tests include the guaiac fecal occult bleeding test (g-FOBT), fecal immunochemical test (FIT), and stool DNA test (DNA-FIT). The g-FOBT and FIT tests detect blood in stool, relying on the premise that cancers will cause ruptures of small vessels, leading to clinically insignificant bleeding [<xref rid="B20-cancers-16-01191" ref-type="bibr">20</xref>,<xref rid="B21-cancers-16-01191" ref-type="bibr">21</xref>]. Although these tests have high sensitivity and specificity, it is worth noting that they have lower sensitivity for pre-malignant lesions such as adenomas (especially smaller ones), which do not invade the blood vessels in the submucosa [<xref rid="B22-cancers-16-01191" ref-type="bibr">22</xref>,<xref rid="B23-cancers-16-01191" ref-type="bibr">23</xref>].</p><p>Detection (and also resection) of precancerous lesions is only possible through colonoscopy, which is considered the gold standard for colorectal cancer screening due to its high sensitivity and specificity, relative safety, and demonstrating reduction of overall colorectal cancer mortality [<xref rid="B24-cancers-16-01191" ref-type="bibr">24</xref>]. Possible limitations to this test include a certain degree of invasiveness and dependence on the training level and experience of the gastroenterologist, leading to discrepancies in the outcomes shown by different studies [<xref rid="B25-cancers-16-01191" ref-type="bibr">25</xref>].</p><p>There are no validated serum biomarkers used in colorectal cancer screening. Serum CEA and CA19-9 markers are not used in screening due to low sensitivity and specificity, but are validated for prognosis and post-resection follow-up [<xref rid="B16-cancers-16-01191" ref-type="bibr">16</xref>,<xref rid="B26-cancers-16-01191" ref-type="bibr">26</xref>].</p><p>The United States Preventive Services Taskforce (USPSTF) highly recommends colorectal cancer screening for patients aged 50&#8211;75 (grade A). For other age groups, the USPSTF suggests screening for patients aged 45&#8211;49 (grade B) and also 76&#8211;85 (grade C&#8212;based on life expectancy and patient risk). Screening modalities include colonoscopy every 10 years, g-FOBT or FIT yearly, with stool DNA-FIT every 1&#8211;3 years, and flexible sigmoidoscopy every 5 years (or flexible sigmoidoscopy every 10 years plus FIT every year) [<xref rid="B27-cancers-16-01191" ref-type="bibr">27</xref>]. The American Cancer Society (ACS) also recommends screening for adults aged 45&#8211;75, selective screening for those 76&#8211;85, and no screening for those over 85. For patients under the age of 45, high-risk features may cause earlier intervention. Patients with relatives diagnosed with colorectal cancer should be screened 10 years before the diagnosis age of the relative. Patients with abdominal or pelvic irradiation history should begin screening 5 years post-intervention or starting at age 30. Patients suffering from inflammatory bowel disease also require colonoscopies at most 8 years after diagnosis, repeated every 1&#8211;3 years. Most importantly, patients with removed polyps during colonoscopy should repeat the test after 3 years maximum, possibly earlier if malignant or high-risk features are found in pathology [<xref rid="B28-cancers-16-01191" ref-type="bibr">28</xref>]. A comparison of colon cancer screening recommendations is offered in <xref rid="cancers-16-01191-t002" ref-type="table">Table 2</xref>, with relevant information about the eligible population and type of testing. In the relevant literature column, we cited the source we found for the information from published guidelines, statements, or relevant articles showing the outcomes of the screening methods that are in place.</p></sec><sec id="sec2dot2-cancers-16-01191"><title>2.2. Breast Cancer</title><p>Breast cancer screening depends mostly on imaging techniques such as mammography, ultrasonography, magnetic resonance imaging, and digital breast tomosynthesis, offering a view of the breast and surrounding tissue, including the axillary region. Unfortunately, there is a lack of consensus on stratifying risk groups and offering which method to which type of patient, with a lack of homogeneity observed at both the international and national level [<xref rid="B47-cancers-16-01191" ref-type="bibr">47</xref>]. Furthermore, the use of mammography is a subject of dispute among clinicians, due to the risk of irradiation and overdiagnosis (i.e., interpreting benign lesions as malignant, leading to overtreatment, burdening the patient psychologically and financially) [<xref rid="B13-cancers-16-01191" ref-type="bibr">13</xref>,<xref rid="B48-cancers-16-01191" ref-type="bibr">48</xref>]. Serum biomarkers such as CA15-3 are not suitable for early detection of breast cancer, since the level rarely increases in patients with early or localized breast cancer, although methods have been proposed to improve the sensitivity in early disease detection [<xref rid="B49-cancers-16-01191" ref-type="bibr">49</xref>]. Currently, CA15-3 is endorsed for surveillance of resected treated breast cancer or for monitoring progression on treatment for metastatic disease [<xref rid="B50-cancers-16-01191" ref-type="bibr">50</xref>].</p><p>The USPSTF recommends that all women aged 50&#8211;74 years receive every two years screening mammography (grade B), with a suggestion for women aged 40&#8211;49 years to receive individualized screening or no mammography [<xref rid="B8-cancers-16-01191" ref-type="bibr">8</xref>,<xref rid="B51-cancers-16-01191" ref-type="bibr">51</xref>]. However, the ACS recommends that women aged 45&#8211;54 receive annual screening mammography and women over the age of 55 annual or biennial mammography until their life expectancy is below 10 years. Women at high risk of breast cancer (such as carriers of BRCA1/2 mutations, women with personal or family history of breast cancer or tumor syndromes such as Li&#8211;Fraumeni or Cowden) or with chest radiation therapy administered between 10&#8211;30 years of age are recommended to receive breast MRI and yearly mammogram screening starting at age 30 [<xref rid="B52-cancers-16-01191" ref-type="bibr">52</xref>]. In <xref rid="cancers-16-01191-t003" ref-type="table">Table 3</xref>, we summarize the breast cancer screening recommendations in different high-income countries. In the relevant literature column, we cited the source we found for the information from published guidelines, statements, or relevant articles showing the outcomes of the screening methods that are in place.</p></sec><sec id="sec2dot3-cancers-16-01191"><title>2.3. Prostate Cancer</title><p>The recommendations for prostate cancer management include digital rectal examination and serum prostate-specific antigen (PSA) determination for screening. However, evidence so far does not demonstrate a survival improvement for PSA screening. A systematic review of five randomized controlled trials, including a total of 721,718 men enrolled, concluded that testing PSA levels does not affect overall mortality, with a significant risk of overdiagnosis and overtreatment [<xref rid="B77-cancers-16-01191" ref-type="bibr">77</xref>]. It is worth remembering that PSA can be detected in the bloodstream after the cancer cells have ruptured the basement layer of the prostate, indicating that the test is conceptually not designed for early tumors or premalignant lesions [<xref rid="B78-cancers-16-01191" ref-type="bibr">78</xref>,<xref rid="B79-cancers-16-01191" ref-type="bibr">79</xref>].</p><p>PSA testing is no longer recommended for prostate cancer screening. Men aged 55&#8211;69 have a C grade recommendation according to the USPSTF, meaning that testing is suggested only if recommended by their physician due to increased risk. For men older than 70, the USPSTF recommends against screening. These changes have led to fewer false-positive diagnoses, but also more metastatic prostate cancer diagnoses in the US Caucasian population. Similarly, the ACS recommends discussing PSA testing with men aged 50 and above with an average risk, aged 45 and above who are African American, those with a first-degree relative below the age of 65 diagnosed with prostate cancer, or those aged 40 with multiple first-degree relatives with early PC diagnoses [<xref rid="B8-cancers-16-01191" ref-type="bibr">8</xref>,<xref rid="B80-cancers-16-01191" ref-type="bibr">80</xref>,<xref rid="B81-cancers-16-01191" ref-type="bibr">81</xref>].</p></sec><sec id="sec2dot4-cancers-16-01191"><title>2.4. Lung Cancer</title><p>Low-dose computed tomography (LDCT) is being offered in the United States for high-risk populations (individuals between the ages of 55 and 80 who have a smoking history equivalent to 30 packs of cigarettes per year, who are currently smoking, or have quit within the last 15 years) to screen for lung cancer. LDCT has good results, showing a 20% reduction in lung cancer mortality compared to the conventional chest X-ray, and also higher sensitivity [<xref rid="B82-cancers-16-01191" ref-type="bibr">82</xref>]. It is worth noting that in Europe, LDCT does not benefit from the same level of adoption, with several trials failing to show benefit [<xref rid="B83-cancers-16-01191" ref-type="bibr">83</xref>,<xref rid="B84-cancers-16-01191" ref-type="bibr">84</xref>]. Also, LDCT can give false-positive results, leading to unnecessary diagnostic and therapeutic procedures, as well as false-negative results, as LDCT may not detect all cancers. Radiation exposure and the high cost of this procedure are also limitations for the large-scale adoption of LDCT [<xref rid="B82-cancers-16-01191" ref-type="bibr">82</xref>,<xref rid="B84-cancers-16-01191" ref-type="bibr">84</xref>,<xref rid="B85-cancers-16-01191" ref-type="bibr">85</xref>].</p><p>Current recommendations from the USPSTF include annual low-dose computer tomography (LDCT) for adults aged 50&#8211;80 with a &gt;20 pack-year history of smoking, and who have either quit within the last 15 years or who are current smokers (grade B recommendation) [<xref rid="B86-cancers-16-01191" ref-type="bibr">86</xref>]. LDCT can be discontinued once a patient has not smoked for at least 15 years or if there would not be a benefit on life expectancy any longer. The 2023 ACS Recommendations for Lung Screening follow the USPSTF recommendations, with no limit to the cessation period (all former smokers eligible for LDCT) [<xref rid="B87-cancers-16-01191" ref-type="bibr">87</xref>].</p></sec><sec id="sec2dot5-cancers-16-01191"><title>2.5. Cervical Cancer</title><p>Screening for cervical cancer can be performed through a Pap smear followed by cytologic examination of the gynecological tract cells and HPV detection (the causal agent in the overwhelming majority of cases). Pap smears are largely regarded as an example of screening success, due to the impressive reduction in cervical cancer mortality after implementing screening strategies using this method [<xref rid="B88-cancers-16-01191" ref-type="bibr">88</xref>], because of the high diagnostic accuracy for premalignant lesions [<xref rid="B89-cancers-16-01191" ref-type="bibr">89</xref>].</p><p>Cervical cytology is another screening method that benefits from a grade A recommendation from the USPSTF, for women aged 21&#8211;29, given every three years, with the choice to continue until 65 years or combine cervical cytology with high-risk human papilloma virus (hrHPV) testing every five years from ages 30&#8211;65. The American College of Obstetrics and Gynecology (ACOG) and the Society of Gynecological Oncology (SGO) have both endorsed these recommendations. ACS also adds primary HPV testing as screening every 5 years from age 25&#8211;65, with co-testing or cytology (according to USPSTF recommendations) offered only when HPV testing is not available [<xref rid="B8-cancers-16-01191" ref-type="bibr">8</xref>,<xref rid="B90-cancers-16-01191" ref-type="bibr">90</xref>,<xref rid="B91-cancers-16-01191" ref-type="bibr">91</xref>]. Further information on cervical cancer screening recommendations across high-income countries is offered below in <xref rid="cancers-16-01191-t004" ref-type="table">Table 4</xref>.</p></sec><sec id="sec2dot6-cancers-16-01191"><title>2.6. Oral Cancer Screening</title><p>Visual oral examination (VOE) is the recommended test for oral cancer and oral potentially malignant disorders (OPMDs), which implies systematic visual inspection and palpation of the oral cavity under a bright light source, to detect suspect lesions of the oral mucosa [<xref rid="B110-cancers-16-01191" ref-type="bibr">110</xref>,<xref rid="B111-cancers-16-01191" ref-type="bibr">111</xref>]. Although most national organizations, including the USPSTF, do not recommend population-based screening through VOE, an RCT showed a reduction in mortality of 81%, and a reduction of 38% in oral cancer incidence [<xref rid="B112-cancers-16-01191" ref-type="bibr">112</xref>] and further studies have demonstrated high sensitivity and specificity for this type of screening [<xref rid="B110-cancers-16-01191" ref-type="bibr">110</xref>,<xref rid="B113-cancers-16-01191" ref-type="bibr">113</xref>]. What is particular about this form of screening is the non-invasiveness, its low cost, and the importance of primary care doctors and dentists, which make the test more accessible and also lowers the burden of manpower needed for population-based screening.</p></sec><sec id="sec2dot7-cancers-16-01191"><title>2.7. Screening for Other Cancers</title><p>Other types of cancers (such as ovarian [<xref rid="B114-cancers-16-01191" ref-type="bibr">114</xref>], pancreatic [<xref rid="B115-cancers-16-01191" ref-type="bibr">115</xref>], or testicular [<xref rid="B116-cancers-16-01191" ref-type="bibr">116</xref>]) may benefit from current methods of screening. However, the current methods have yet to prove a reduction in mortality or reduction in the financial burden, thus lacking a consensus on a standardized valid test. This underlines the need for new validated methods to improve the current management of early detections.</p></sec></sec><sec id="sec3-cancers-16-01191"><title>3. Fantastic Biomarkers and Where to Find Them</title><p>Cancer presence can be discovered in its pre-symptomatic phase through careful evaluation of bodily fluids, where trace amounts of catabolites, nucleic acids, and peptides might reflect the existence of complex mechanisms involved in tumorigenesis and host response directed towards the malignancy. Direct vascular invasion permits cancer cells to be found in blood, but other processes such as necrosis, apoptosis, micro-vesicle budding, and phagocytosis (which occur earlier), or the formation of auto-antibodies, contribute with a host of byproducts that can serve as markers of early-stage disease. As such, bodily fluids can function as a strategic key point of early cancer detection [<xref rid="B117-cancers-16-01191" ref-type="bibr">117</xref>,<xref rid="B118-cancers-16-01191" ref-type="bibr">118</xref>,<xref rid="B119-cancers-16-01191" ref-type="bibr">119</xref>].</p><sec id="sec3dot1-cancers-16-01191"><title>3.1. Blood Tumor Markers</title><sec id="sec3dot1dot1-cancers-16-01191"><title>3.1.1. Circulating Tumor Cells</title><p>Circulating tumor cells (CTCs) occur as part of the natural evolution of malignancies towards metastasis. Although this process usually involves lymphovascular invasion, CTCs have been nonetheless found before imaging detection of a primary tumor, indicating a potential value in cancer screening [<xref rid="B120-cancers-16-01191" ref-type="bibr">120</xref>,<xref rid="B121-cancers-16-01191" ref-type="bibr">121</xref>,<xref rid="B122-cancers-16-01191" ref-type="bibr">122</xref>,<xref rid="B123-cancers-16-01191" ref-type="bibr">123</xref>].</p><p>Huang et al. showed an increase in mean CTC for patients with early (stage I/II) lung, colorectal, gastric, liver, and esophageal cancer, providing a glimpse of establishing a new biomarker, by using EpCAM+/vimentin+ specific immunomagnetic beads for CTC isolation [<xref rid="B124-cancers-16-01191" ref-type="bibr">124</xref>,<xref rid="B125-cancers-16-01191" ref-type="bibr">125</xref>]. Other possible strategies include the analysis of circulating ensembles of tumor-associated cells (C-ETACs), defined as clusters of pan-cytokeratin and EpCAM-positive cells (at least three). This method has so far outperformed conventional CTC assays, with 89.8% sensitivity and 97% specificity [<xref rid="B126-cancers-16-01191" ref-type="bibr">126</xref>,<xref rid="B127-cancers-16-01191" ref-type="bibr">127</xref>].</p></sec><sec id="sec3dot1dot2-cancers-16-01191"><title>3.1.2. Plasma Cell-Free Nucleic Acids</title><p>As described earlier, conventional protein tumor markers such as carcinoembryonic antigen (CEA), cancer antigens 15-3 (CA15-3) or 19-9 (CA19-9), are routinely used in clinical practice, but they suffer from low sensitivity, especially at early stages, and are not routinely used for screening [<xref rid="B128-cancers-16-01191" ref-type="bibr">128</xref>]. Novel tests such as liquid biopsies hold promise for accurate screening of multiple tumor types and represent an exciting avenue for the research and development of new biomarkers [<xref rid="B129-cancers-16-01191" ref-type="bibr">129</xref>,<xref rid="B130-cancers-16-01191" ref-type="bibr">130</xref>,<xref rid="B131-cancers-16-01191" ref-type="bibr">131</xref>].</p><p>Circulating biomarkers, including microRNAs (miRNAs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA), represent active targets as biomarkers of cancer detections and MCED can be achieved through genome sequencing of plasma, as shown by several groups. Malignancy can be detected and tumor sites, including ovary, liver, stomach, pancreas, esophagus, colorectum, lung or breast, can be predicted using nucleic acid assays [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>,<xref rid="B132-cancers-16-01191" ref-type="bibr">132</xref>].</p><p>One of the most discussed tests available is the Galleri (GRAIL) test, which is a targeted methylation assay combined with a machine learning classifier for the detection and discrimination of more than 50 cancers using cfDNA. The test obtained 54.9% sensitivity and 99.3% specificity, with 93% accuracy for tissue-of-origin (TOO) prediction [<xref rid="B133-cancers-16-01191" ref-type="bibr">133</xref>,<xref rid="B134-cancers-16-01191" ref-type="bibr">134</xref>,<xref rid="B135-cancers-16-01191" ref-type="bibr">135</xref>]. Further MCED tests are showing promising results, and we are eagerly awaiting clinical trials to demonstrate their screening value. A review conducted by Brito-Rocha et al. provides further insights into the development of biomarkers that can be evaluated through liquid biopsies, including the clinical trials where these methods were used. The article provides a comprehensive summary of the state of the art in liquid biopsy for MCED research and further encourages the need for thorough clinical research of the new screening tools for them to be used in current practice [<xref rid="B18-cancers-16-01191" ref-type="bibr">18</xref>]. As a tribute to their work, we updated <xref rid="cancers-16-01191-t003" ref-type="table">Table 3</xref> from their manuscript with the current state of the art in clinical trials for the validation of MCED tests (<xref rid="cancers-16-01191-t005" ref-type="table">Table 5</xref> and <xref rid="cancers-16-01191-t006" ref-type="table">Table 6</xref>).</p></sec><sec id="sec3dot1dot3-cancers-16-01191"><title>3.1.3. Extracellular Vesicle-Based Tests for MCED</title><p>Extracellular vesicles (EVs), such as exosomes, microvesicles, and apoptotic bodies, are lipid membrane vesicles that get secreted by a large number of cells, including cancer cells. They play major roles in cell&#8211;cell-mediated communication, including molecule transportation. Whether they are constituted by nucleic acids, proteins, or metabolites, these molecules can be of interest as cancer biomarkers [<xref rid="B136-cancers-16-01191" ref-type="bibr">136</xref>,<xref rid="B137-cancers-16-01191" ref-type="bibr">137</xref>,<xref rid="B138-cancers-16-01191" ref-type="bibr">138</xref>,<xref rid="B139-cancers-16-01191" ref-type="bibr">139</xref>].</p><p>Goldvaser et al. studied the use of exosome human telomerase reverse transcriptase (hTERT) mRNA as a minimally invasive pan-cancer biomarker [<xref rid="B140-cancers-16-01191" ref-type="bibr">140</xref>]. Their study showed a 62% sensitivity and 100% specificity for detecting 15 cancer types, both solid and hematologic.</p><p>The Verita<sup>TM</sup> test using EV-protein profiling combined with machine learning is capable of detecting pancreatic, ovarian, and bladder cancer in early, curative stages (stage I and II), with varying degrees of sensitivity pancreatic cancer (95.5%), ovarian cancer (74.4%), and bladder cancer (43.8%) [<xref rid="B141-cancers-16-01191" ref-type="bibr">141</xref>]. Most encouragingly, targeting the CD9+ EVs and aptamer recognition of CD63/EpCAM/MUC1 (epithelial markers), carcinomas were detected with 100% sensitivity and specificity, indicating that specific targeting of tumor type-specific proteins can be used for both cancer screening and identification of the tumor&#8217;s origin [<xref rid="B142-cancers-16-01191" ref-type="bibr">142</xref>,<xref rid="B143-cancers-16-01191" ref-type="bibr">143</xref>].</p></sec></sec><sec id="sec3dot2-cancers-16-01191"><title>3.2. Non-Invasive Early Cancer Detection Using Indirect Media&#8212;Saliva, Tears, Urine, Breath</title><p>Blood is not the only compartment where biomarkers can be identified. Other media, for instance, urine, saliva, or breath, may contain materials derived from circulation. These molecules can be interrogated through non-invasive testing for the oncogenic pathways they uncover [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>].</p><p>Although the glomerular filter impedes the passing of larger molecules, extracellular vesicles containing tumor-specific RNA signatures can be detected through a nanowire device embedded in a microfluidic system, as described by Takao Yasui et al. [<xref rid="B144-cancers-16-01191" ref-type="bibr">144</xref>].</p><p>Furthermore, saliva is an easily available bodily fluid that may emerge as a haven for MCED development, as innovations in the assay of circulatory biomarkers have been exciting thus far. The review by Kaczor-Urbanowicz et al. delves deeper into the recent progress made in salivaomics and the impact on cancer diagnosis [<xref rid="B145-cancers-16-01191" ref-type="bibr">145</xref>].</p><p>Tear samples, although difficult to collect, maybe an interesting avenue for MCED biomarker discovery, as a study by Daily et al. has identified several protein markers in tears of early-stage breast cancer [<xref rid="B146-cancers-16-01191" ref-type="bibr">146</xref>].</p><p>Last but not least, exhaled breath can become a viable site for biomarker identification, with devices showing promising results in detecting multiple cancers, including respiratory, gastrointestinal, or gynecological cancers. We recommend the systematic review done by Krilaviciute et al. for further insights on exhaled breath biomarker discovery [<xref rid="B147-cancers-16-01191" ref-type="bibr">147</xref>].</p></sec><sec id="sec3dot3-cancers-16-01191"><title>3.3. Tumor Exfoliation</title><p>Anatomic corridors such as the gastrointestinal (GI) tract or the female reproductive tracts are lined by epithelial cells, which have a physiological tendency to exfoliate into a common efflux route. Similar to CTCs, the excretory medium for these exfoliates can be interrogated for clinically useful biomarkers, as exfoliation occurs from both precursor lesions and earliest-stage cancers, even before any substantial invasion can occur [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>].</p><p>The stool can be a valuable sample for colorectal cancer screening, since even precursor lesions can be accurately detected using multi-target DNA tests, achieving detection rates comparable to those of colonoscopy [<xref rid="B148-cancers-16-01191" ref-type="bibr">148</xref>,<xref rid="B149-cancers-16-01191" ref-type="bibr">149</xref>,<xref rid="B150-cancers-16-01191" ref-type="bibr">150</xref>]. Attempts at improving diagnostic accuracy have been made by targeting molecular debris in stool, including abnormal DNA (such as mutant KRAS, actin, FIT, aberrantly methylated BMP, and NDRG4 promoter regions), using the Cologuard<sup>&#174;</sup> stool DNA test. Unfortunately, the test had lower sensitivity towards adenomas, thus limiting its preventive role, and lower specificity compared to FIT (87&#8211;90% compared to 95&#8211;96%) [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>,<xref rid="B150-cancers-16-01191" ref-type="bibr">150</xref>]. The mt-sRNA ColoSense<sup>&#174;</sup> test showed improvements in sensitivity (94%), but remains insufficient for advanced adenomas (46%) [<xref rid="B151-cancers-16-01191" ref-type="bibr">151</xref>]. However, molecular tumor fingerprinting of early cancers using stool samples remains an attractive venue in biomarker research. Also, compared to the standard fecal occult blood test, early data suggest that stool testing can be expanded to include the previously unscreened upper GI tract as well. However, techniques need to be optimized and rigorously tested in the clinic to be adequately assessed to have a pan-GI screening test [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>]. In our opinion, the diagnostic yield of these tests is dependent on accurately predicting the mutations occurring earliest in tumorigenesis, which may influence the transition between premalignant lesions towards neoplasia [<xref rid="B152-cancers-16-01191" ref-type="bibr">152</xref>].</p><p>Detecting gynecological neoplasms with tampons is a concept that has been proven by analyzing methylated DNA markers extracted from vaginal tampons. Also, molecular analysis may allow the detection of both endometrial and ovarian cancer using a conventional cervical Papanicolaou test, further expanding the clinical utility of this routine test. Further clinical trials are needed to demonstrate the practicality of these tests, as they might turn a single cancer detection test into an MCED examination [<xref rid="B153-cancers-16-01191" ref-type="bibr">153</xref>,<xref rid="B154-cancers-16-01191" ref-type="bibr">154</xref>].</p><table-wrap position="anchor" id="cancers-16-01191-t005" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01191-t005_Table 5</object-id><label>Table 5</label><caption><p>Clinical trials conducted/ongoing for validation of multi-cancer early detection tests (updated and redesigned from <xref rid="cancers-16-01191-t003" ref-type="table">Table 3</xref> of Brito-Rocha et al. [<xref rid="B18-cancers-16-01191" ref-type="bibr">18</xref>]).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial ID</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MCED Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status (as of February 2024)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Est. Completion</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Enrolled</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Publications</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02889978">NCT02889978</ext-link></bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">CCGA, GRAIL-001</td><td align="center" valign="middle" rowspan="1" colspan="1">Galleri</td><td align="center" valign="middle" rowspan="1" colspan="1">GRAIL, LLC</td><td align="center" valign="middle" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" rowspan="1" colspan="1">March 2024</td><td align="center" valign="middle" rowspan="1" colspan="1">15,254</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B135-cancers-16-01191" ref-type="bibr">135</xref>,<xref rid="B155-cancers-16-01191" ref-type="bibr">155</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03085888">NCT03085888</ext-link></bold>
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">STRIVE, GRAIL-002</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Galleri</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">GRAIL, LLC</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">May 2025</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">99,481</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03934866">NCT03934866</ext-link></bold>
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">SUMMIT</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Galleri (combined with LDCT)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">University College London and Grail</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">August 2030</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">13,035</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B156-cancers-16-01191" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04241796">NCT04241796</ext-link></bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PATHFINDER, GRAIL-007</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Galleri</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GRAIL, LLC</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6662</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B157-cancers-16-01191" ref-type="bibr">157</xref>,<xref rid="B158-cancers-16-01191" ref-type="bibr">158</xref>,<xref rid="B159-cancers-16-01191" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05155605">NCT05155605</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PATHFINDER2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Galleri</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRAIL, LLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">January 2028</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05205967">NCT05205967</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">REFLECTION</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Galleri</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRAIL, LLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">August 2026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05611632">NCT05611632</ext-link>,</bold>
<bold>ISRCTN91431511</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NHS-Galleri, GRAIL-009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Galleri</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRAIL, Bio UK Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">February 2026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">140,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-cancers-16-01191" ref-type="bibr">160</xref>,<xref rid="B161-cancers-16-01191" ref-type="bibr">161</xref>,<xref rid="B162-cancers-16-01191" ref-type="bibr">162</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05235009">NCT05235009</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LEV87A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAGome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elypta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">March 2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9170</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B163-cancers-16-01191" ref-type="bibr">163</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05295017">NCT05295017</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LEV93A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAGome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elypta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">March 2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1256</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05780957">NCT05780957</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi-Cancer Early Detection (MCED) of Firefighters</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAGome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elypta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">January 2031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000 (estimated)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05227534">NCT05227534</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PREVENT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OverC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Burning Rock Dx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">January 2029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04972201">NCT04972201</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PROMISE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OverC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chinese Academy of Medical Sciences and<break/>Burning Rock Dx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2305</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-cancers-16-01191" ref-type="bibr">164</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04822792">NCT04822792</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRESCIENT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OverC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chinese Academy of Medical Sciences and<break/>Burning Rock Dx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,879</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04820868">NCT04820868</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THUNDER</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OverC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shanghai Zhongshan Hospital and<break/>Burning Rock Dx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2508</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B165-cancers-16-01191" ref-type="bibr">165</xref>,<xref rid="B166-cancers-16-01191" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04817306">NCT04817306</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PREDICT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OverC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shanghai Zhongshan Hospital and<break/>Burning Rock Dx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,206</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03517332">NCT03517332</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DEEPGEN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quantgene Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">675</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-cancers-16-01191" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03967652">NCT03967652</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Na-nose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anhui Medical University</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B168-cancers-16-01191" ref-type="bibr">168</xref>,<xref rid="B169-cancers-16-01191" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05366881">NCT05366881</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAMPERR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adela, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">December 2026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B170-cancers-16-01191" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05254834">NCT05254834</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vallania</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Freenome Holdings Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">June 2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5400</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05227261">NCT05227261</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K-DETEK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPOT-MAS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gene Solutions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B171-cancers-16-01191" ref-type="bibr">171</xref>,<xref rid="B172-cancers-16-01191" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05159544">NCT05159544</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FuSion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Singlera Genomics Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-cancers-16-01191" ref-type="bibr">173</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405557">NCT04405557</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PREDICT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geneplus-Beijing Co.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">757</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Article under review</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02662621">NCT02662621</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EXODIAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Centre Georges Francois Leclerc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-cancers-16-01191" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04197414">NCT04197414</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yonsei University</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">December 2029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03951428">NCT03951428</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LifeStory Health Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03869814">NCT03869814</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bluestar Genomics Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">660</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02612350">NCT02612350</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathway Genomics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1106</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06011694">NCT06011694</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The Jinling Cohort</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERCURY test</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanjing Shihejiyin Technology, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May 2027</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,000 (estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-cancers-16-01191" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05633342">NCT05633342</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CADENCE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MiRXES MCST</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MiRXES Pte Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May 2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,000 (estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04825834">NCT04825834</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DELFI-L101</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DELFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delfi Diagnostics Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">June 2026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2660 (estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B176-cancers-16-01191" ref-type="bibr">176</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05306288">NCT05306288</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DELFI-L201 (CASCADE-LUNG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delfi Diagnostics Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">March 2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15,000 (estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05492617">NCT05492617</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DETECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rigshospitalet, Denmark</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3628</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B177-cancers-16-01191" ref-type="bibr">177</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05435066">NCT05435066</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CORE-HH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harbringer Hx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harbringer Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">July 2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,000 (estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B178-cancers-16-01191" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05117840">NCT05117840</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SHIELD</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LUNAR-2</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Guardant Health, Inc.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">January 2026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9000 (estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-cancers-16-01191" ref-type="bibr">179</xref>,<xref rid="B180-cancers-16-01191" ref-type="bibr">180</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04136002">NCT04136002</ext-link></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ECLIPSE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">January 2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40,000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-cancers-16-01191" ref-type="bibr">181</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="cancers-16-01191-t006" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01191-t006_Table 6</object-id><label>Table 6</label><caption><p>Technical description of MCED Tests currently on clinical trials conducted/ongoing for validation of multi-cancer early detection tests (updated and redesigned from <xref rid="cancers-16-01191-t003" ref-type="table">Table 3</xref> of Brito-Rocha et al. [<xref rid="B18-cancers-16-01191" ref-type="bibr">18</xref>]).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MCED Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Publications</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method of Detection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tumor Types</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Galleri</td><td align="center" valign="middle" rowspan="1" colspan="1">GRAIL, LLC</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B135-cancers-16-01191" ref-type="bibr">135</xref>,<xref rid="B155-cancers-16-01191" ref-type="bibr">155</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">plasma</td><td align="center" valign="middle" rowspan="1" colspan="1">Targeted methylation assay (cfDNA), combined with a machine learning classifier for detecting (54.9% sensitivity, 99.3% specificity) and discriminating TOO (93% accuracy) [<xref rid="B134-cancers-16-01191" ref-type="bibr">134</xref>,<xref rid="B135-cancers-16-01191" ref-type="bibr">135</xref>].</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;40 different tumor types: GI, hematological, head and neck, lung, ovary, etc.</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GAGome</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Elypta</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B163-cancers-16-01191" ref-type="bibr">163</xref>]</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">plasma and urine</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Free glycosaminoglycan profiles (GAGome)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">14 different cancers: gliomas, genito-urinary, etc.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OverC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Burning Rock Dx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-cancers-16-01191" ref-type="bibr">164</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted methylation sequencing assay (ELSA-seq) combined with machine learning for cancer detection (80.6% sensitivity, 98.3% specificity) and TOO discrimination (81.0% accuracy)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung, colorectal, liver, ovarian, pancreatic, esophageal [<xref rid="B182-cancers-16-01191" ref-type="bibr">182</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DEEPGEN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quantgene Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-cancers-16-01191" ref-type="bibr">167</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS combined with machine learning for cancer detection (57% sensitivity, 95% specificity)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung, breast, colorectal, prostate, bladder, pancreatic, and liver</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Na-nose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anhui Medical University</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B168-cancers-16-01191" ref-type="bibr">168</xref>,<xref rid="B169-cancers-16-01191" ref-type="bibr">169</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exhaled breath</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticle sensors for Volatile Organic Compounds found in exhaled breath</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Head and neck, lung, breast, colorectal, etc.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adela, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B170-cancers-16-01191" ref-type="bibr">170</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cfMeDIP-seq [<xref rid="B183-cancers-16-01191" ref-type="bibr">183</xref>] combined with machine learning</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kidney, pancreas, lung, gliomas, etc.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPOT-MAS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gene Solutions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B171-cancers-16-01191" ref-type="bibr">171</xref>,<xref rid="B172-cancers-16-01191" ref-type="bibr">172</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NGS sequencing of ctDNA to detect genome-wide hypomethylation, targeted hypermethylated regions, genome-wide copy number variation, length profile of ctDNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastric, lung, breast, etc.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Singlera Genomics Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-cancers-16-01191" ref-type="bibr">173</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA methylation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">lung, esophagus, stomach, liver, pancreatic and colorectal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geneplus-Beijing Co.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Article under review</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cfDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatic, pancreatic, ovarian, breast, colorectal and gastric cancer.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Centre Georges Francois Leclerc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-cancers-16-01191" ref-type="bibr">174</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood and urine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis of HSP70-exosomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast, lung, ovarian</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yonsei University</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood and urine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ctDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urological malignancies</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LifeStory Health Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Menstrual blood</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast, endometrial, lung</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bluestar Genomics Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cfDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreatic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathway Genomics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cfDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancancer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERCURY test</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanjing Shihejiyin Technology, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-cancers-16-01191" ref-type="bibr">175</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cfDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver, lung, colorectal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MiRXES MCST</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MiRXES Pte Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miRNA expression in tandem with DNA methylation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">lung, breast, colorectal, liver, stomach, esophageal, ovarian, pancreatic, and prostate</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DELFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delfi Diagnostics Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B176-cancers-16-01191" ref-type="bibr">176</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cfDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung, liver cancer</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harbringer Hx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harbringer Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B178-cancers-16-01191" ref-type="bibr">178</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cfDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variety of solid and hematological cancers</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUNAR-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guardant Health, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-cancers-16-01191" ref-type="bibr">179</xref>,<xref rid="B180-cancers-16-01191" ref-type="bibr">180</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">plasma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ctDNA analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon, lung cancer</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec4-cancers-16-01191"><title>4. Expanding the Horizons towards Universal Cancer Screening</title><sec id="sec4dot1-cancers-16-01191"><title>4.1. Improved Imaging Techniques</title><p>Conceptually, computed tomography (CT) scans with or without contrast enhancement of the whole body can be considered MCED. However, CT scans have low sensitivity and specificity, and pose a significant threat of side effects, due to irradiation and contrast-induced nephropathy, which severely limit the repeated use for one person [<xref rid="B184-cancers-16-01191" ref-type="bibr">184</xref>,<xref rid="B185-cancers-16-01191" ref-type="bibr">185</xref>].</p><p>Next-generation approaches towards imaging involve molecular, nanoparticle, and fluorescent constructs, which have sparked clinical interest for their potential to capture a precise in vivo snapshot of the person&#8217;s oncological status, providing details for both screening and treatment monitoring. Further research is warranted to optimize the technical details and to provide information about the examination performance and clinical outcomes [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>,<xref rid="B186-cancers-16-01191" ref-type="bibr">186</xref>,<xref rid="B187-cancers-16-01191" ref-type="bibr">187</xref>,<xref rid="B188-cancers-16-01191" ref-type="bibr">188</xref>].</p></sec><sec id="sec4dot2-cancers-16-01191"><title>4.2. Volatile Organic Compounds</title><p>Byproducts of metabolic processes involving cellular transformation and tumorigenesis can be found in trace amounts in urine and expired breath. These catabolites and the patterns of volatile organic compounds (VOCs) can be studied, with numerous studies indicating potential relationships between VOCs and different cancers. It has been suggested that in breast cancer patients, six specific VOCs could be used for a screening test. Other studies have highlighted the importance of VOCs in cancers such as prostate, kidney, or lung [<xref rid="B7-cancers-16-01191" ref-type="bibr">7</xref>,<xref rid="B133-cancers-16-01191" ref-type="bibr">133</xref>,<xref rid="B169-cancers-16-01191" ref-type="bibr">169</xref>,<xref rid="B189-cancers-16-01191" ref-type="bibr">189</xref>,<xref rid="B190-cancers-16-01191" ref-type="bibr">190</xref>,<xref rid="B191-cancers-16-01191" ref-type="bibr">191</xref>,<xref rid="B192-cancers-16-01191" ref-type="bibr">192</xref>,<xref rid="B193-cancers-16-01191" ref-type="bibr">193</xref>,<xref rid="B194-cancers-16-01191" ref-type="bibr">194</xref>,<xref rid="B195-cancers-16-01191" ref-type="bibr">195</xref>,<xref rid="B196-cancers-16-01191" ref-type="bibr">196</xref>,<xref rid="B197-cancers-16-01191" ref-type="bibr">197</xref>].</p><p>So far, volatilome research has been impeded by technical issues and a high financial burden, requiring complex technology for the identification of specific patterns. However, a biosensor has recently been proposed, <italic toggle="yes">Caenorhabditis elegans</italic>, a nematode with a refined olfactory sense (with over 1200 olfactory receptor-like genes, encoding 1.5 times as many different types of olfactory receptors as a dog, capable of detecting subtle odorant concentration changes in its habitat). With the observation that <italic toggle="yes">C. elegans</italic> is attracted to urine from cancer patients, but avoids urine from healthy persons, a team led by Hirotsu et al. perfected an innovative, highly sensitive cancer screening test called N-Nose, which has been available in Japan since 2020. It is capable of detecting the presence of cancer for 15 malignancies, with a sensitivity of 87.5% and specificity of 90.2%. Unfortunately, N-Nose only correlates with the presence/absence of cancer, without the capability of pinpointing the cancer types. However, efforts are being made to further understand the chemotaxis mechanism of <italic toggle="yes">C. elegans</italic> and methods of perfecting this potentially powerful screening tool. It is important to mention that the N-Nose behavioral assay has been thoroughly evaluated in clinical studies with large cohorts of patients, showing reliable results. Also, the results have been replicated at other prestigious institutions in the US and Italy [<xref rid="B7-cancers-16-01191" ref-type="bibr">7</xref>,<xref rid="B128-cancers-16-01191" ref-type="bibr">128</xref>,<xref rid="B198-cancers-16-01191" ref-type="bibr">198</xref>,<xref rid="B199-cancers-16-01191" ref-type="bibr">199</xref>,<xref rid="B200-cancers-16-01191" ref-type="bibr">200</xref>,<xref rid="B201-cancers-16-01191" ref-type="bibr">201</xref>,<xref rid="B202-cancers-16-01191" ref-type="bibr">202</xref>,<xref rid="B203-cancers-16-01191" ref-type="bibr">203</xref>].</p></sec><sec id="sec4dot3-cancers-16-01191"><title>4.3. Always on PATROL for Early Lung Cancer</title><p>A particular assay that has drawn the authors&#8217; attention has been the diagnostic platform PATROL (point-of-care aerosolizable nanosensors with tumor-responsive oligonucleotide barcodes), which is currently tested for the early diagnosis of lung cancer, but with the potential to become an MCED test for airway cancers. The diagnostic platform incorporates three modules, as follows. (1) Artificially synthesized low-plex activity-based nanomers (ABNs), consisting of protease substrates (for dysregulated proteases produced by tumoral cells on the lung epithelia) conjugated to eight-armed PEG nanoscaffolds with single-stranded modified DNA 20-mers. These molecules are nebulized through a (2) portable inhalation unit, and then delivered to the lung, where the DNA barcodes are liberated upon substrate cleavage by dysregulated proteases associated with early lung adenocarcinoma, shed into the systemic circulation, and then excreted by the kidneys in the urine. The urine is then sampled (2 h after inhalation), and the DNA barcodes are analyzed through a (3) multiplex lateral flow assay, quantified, and classified to provide diagnosis. The results of this test have so far been promising with high sensitivity and specificity for stage I/II lung adenocarcinoma [<xref rid="B204-cancers-16-01191" ref-type="bibr">204</xref>]. This particular assay sparked our interest not only for the good results shown so far and the cost-effectiveness promised by the authors but also for the concept of activity-based diagnostics (ABD), in which the tumoral metabolic processes are leveraged to provide the result via the excretion of a synthesized biomarker. We believe that variants of this concept can be proposed and used for other cancers by mastering the triad this assay proposes: (1) a highly sensible, conjugable complex consisting of a readable DNA barcode and a cleavable enzyme substrate that can be targeted by dysregulated tumoral enzymes; (2) an accessible, preferably non-invasive entry route for this complex, which cannot be degraded along this path, towards the organ(s) in which cancer is screened; and (3) an excretion route where the DNA can be available for analyzing and interpretation of the results.</p></sec></sec><sec sec-type="discussion" id="sec5-cancers-16-01191"><title>5. Discussion on the Prospect of Universal Cancer Screening</title><sec id="sec5dot1-cancers-16-01191"><title>5.1. &#8220;One Test to Rule Them All&#8221; vs. &#8220;One Organ at a Time&#8221;</title><p>The universal cancer screening approach is a paradigm-changing approach for the early detection of cancers through the non-invasive interrogation of multiple markers and media on the possible existence of malignancy. With the potential of multi-organ detection, we can imagine tests that can include all cancers in a single efficient modality of testing, which would be potentially both cost- and life-saving. Perhaps, in the era of treating cancer using &#8220;precision medicine&#8221; tailored to the most intimate characteristics of tumor cell biology, a &#8220;one test to rule them all&#8221; approach toward cancer screening would be a match made in heaven, as simulations have already modeled, promising reductions of up to a quarter in all cancer-related deaths in patients aged 50&#8211;79 years in the United States and a reduction of almost 80% for late-stage (III, IV) disease [<xref rid="B7-cancers-16-01191" ref-type="bibr">7</xref>,<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>,<xref rid="B205-cancers-16-01191" ref-type="bibr">205</xref>].</p></sec><sec id="sec5dot2-cancers-16-01191"><title>5.2. Aggregate Prevalence</title><p>The value of a screening intervention is given by the combination of a low estimated number of persons that need to be screened to detect one cancer (NNS), and a high positive predictive value (PPV&#8212;the probability that a screening test indicates the presence of a tumor). Given that prevalence varies across tumor locations and subtypes, a single test that incorporates multiple targets can decrease the NNS. Furthermore, aggregating multiple cancers with different prevalence rates in a universal test would yield higher PPVs than single-organ screening. This argument has been comprehensively supported by Ahlquist et. al, offering an insightful rationale for the need for MCED [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>].</p></sec><sec id="sec5dot3-cancers-16-01191"><title>5.3. Manpower Considerations</title><p>It is difficult to estimate if MCED screening would represent a burden or a relief for medical healthcare workers. One of the pivotal requirements of a successful, efficient screening program is a central, well-funded authority, responsible for setting recommendations and organizing the framework of how these recommendations can be applied (see <xref rid="cancers-16-01191-t002" ref-type="table">Table 2</xref>, <xref rid="cancers-16-01191-t003" ref-type="table">Table 3</xref> and <xref rid="cancers-16-01191-t004" ref-type="table">Table 4</xref>). It is most encouraging to see cancer screening programs offering eligible population tests that do not require healthcare workers (such as FIT) at home [<xref rid="B35-cancers-16-01191" ref-type="bibr">35</xref>]. These tests are generally accompanied by greater compliance from the general public because of their non-invasiveness, privacy, and simple nature (see <xref rid="cancers-16-01191-t001" ref-type="table">Table 1</xref>). Collecting samples such as stool, urine, or saliva can be done by the patient and sent through the mail to a specialized laboratory. Though most of the MCED screening tests in clinical trials (see <xref rid="cancers-16-01191-t005" ref-type="table">Table 5</xref> and <xref rid="cancers-16-01191-t006" ref-type="table">Table 6</xref>) require blood samples, this should not be an impediment, as these tests can be offered simultaneously with other regular health checkups that require this minimally invasive medical procedure. In conclusion, we believe that MCED would not burden already-pressured health services.</p></sec><sec id="sec5dot4-cancers-16-01191"><title>5.4. Cost-Effectiveness</title><p>Most cancers are diagnosed in late stages, needing expensive long-term systemic treatment, which leads to an increase in the economic burden of cancers. In 2020 alone, the US healthcare system covered 157.7 billion USD, and 16.1 million cancer patients had out-of-pocket expenses, with a quarter of them declaring they had difficulties paying the bills. Mitigation of the economic, medical, and psychological issues related to late-stage diagnosis is an overarching drive of universal cancer screening. Such expenses warrant investments in MCED, as tests such as Galleri (~945 USD), or N-Nose (~109 USD) can be cheaper than PET-CT, for instance (~1100 USD). Large-scale implementation of these tests can lower the price even further, and the biggest benefit would be offering prompt treatment, with lower financial burden for both the patient and healthcare providers [<xref rid="B7-cancers-16-01191" ref-type="bibr">7</xref>,<xref rid="B206-cancers-16-01191" ref-type="bibr">206</xref>]. The reductions in the financial burden have been estimated by Hackshaw et al. and Tafazzoli et al., showing that hypothetically MCED could reduce the cost per cancer treatment by up to 5421 USD per cancer patient [<xref rid="B19-cancers-16-01191" ref-type="bibr">19</xref>,<xref rid="B207-cancers-16-01191" ref-type="bibr">207</xref>]. With permission, we decided to present the estimated data from Hackshaw et al.&#8217;s article in <xref rid="cancers-16-01191-t007" ref-type="table">Table 7</xref>.</p></sec><sec id="sec5dot5-cancers-16-01191"><title>5.5. Bioinformatics and Artificial Intelligence (AI)</title><p>Biomarker research has evolved in close relation with bioinformatic development. Since the development of the Cancer Genome Atlas (TCGA) project, large databases containing valuable data on the multisystem biology features of multiple tumor types have led to the development of data mining methods to propose valuable biomarkers [<xref rid="B18-cancers-16-01191" ref-type="bibr">18</xref>,<xref rid="B208-cancers-16-01191" ref-type="bibr">208</xref>,<xref rid="B209-cancers-16-01191" ref-type="bibr">209</xref>,<xref rid="B210-cancers-16-01191" ref-type="bibr">210</xref>,<xref rid="B211-cancers-16-01191" ref-type="bibr">211</xref>,<xref rid="B212-cancers-16-01191" ref-type="bibr">212</xref>,<xref rid="B213-cancers-16-01191" ref-type="bibr">213</xref>,<xref rid="B214-cancers-16-01191" ref-type="bibr">214</xref>]. Examples include the study of molecular aberrations of the SST gene for multiple GI cancers [<xref rid="B215-cancers-16-01191" ref-type="bibr">215</xref>], the difference in HSP90&#945; protein across 9 different tumors [<xref rid="B216-cancers-16-01191" ref-type="bibr">216</xref>], or the identification of CpG markers to detect 27 cancer types [<xref rid="B217-cancers-16-01191" ref-type="bibr">217</xref>].</p><p>Furthermore, the existence of large databases allows machine learning algorithms to be developed and trained to improve the detection capacity of current biomarkers. Several neural network-based algorithms have been developed to improve detection sensitivity and specificity, as well as tumor-of-origin (TOO) discrimination [<xref rid="B18-cancers-16-01191" ref-type="bibr">18</xref>]. The undeniable benefit of artificial intelligence becomes evident when we observe that the vast majority of MCED tests with ongoing trials have applied deep learning algorithms to improve their diagnostic yield (<xref rid="cancers-16-01191-t006" ref-type="table">Table 6</xref>). As such, it is important to recognize AI as a key element of biomarker discovery that boosts the output and outcomes of MCED tests.</p></sec></sec><sec sec-type="conclusions" id="sec6-cancers-16-01191"><title>6. Conclusions</title><p>The dream of universal cancer screening remains elusive at the moment. However, translational studies coupled with clinical research offer us an optimistic view for the future, as we move closer to significant improvements in oncological outcomes through early diagnosis and curative treatment. We are hopeful that the tools presented in this article will soon be incorporated into current guidelines for screening the general population and will help improve the survival rate of cancer patients.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, L.N.G. and M.-A.P.; methodology, L.N.G. and R.M.A.; software, M.-A.P.; writing&#8212;original draft preparation, M.-A.P.; writing&#8212;review and editing, L.N.G. and O.G.T.; supervision, L.N.G. and O.G.T.; project administration, R.M.A. and L.N.G.; tables and figures&#8212;M.-A.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-16-01191"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B2-cancers-16-01191"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Randi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Martos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giusti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gavin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flego</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neamtiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dimitrova</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The European Cancer Burden in 2020: Incidence and Mortality Estimates for 40 Countries and 25 Major Cancers</article-title><source>Eur J Cancer</source><year>2021</year><volume>157</volume><fpage>308</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.07.039</pub-id><pub-id pub-id-type="pmid">34560371</pub-id><pub-id pub-id-type="pmcid">PMC8568058</pub-id></element-citation></ref><ref id="B3-cancers-16-01191"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torre</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global Cancer Incidence and Mortality Rates and Trends&#8212;An Update</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2016</year><volume>25</volume><fpage>16</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-15-0578</pub-id><pub-id pub-id-type="pmid">26667886</pub-id></element-citation></ref><ref id="B4-cancers-16-01191"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ponti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anttila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ronco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Senore</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vale</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Segnan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tomatis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Primic &#381;akelj</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Status of Implementation and Organization of Cancer Screening in The European Union Member States&#8212;Summary Results from the Second European Screening Report</article-title><source>Int. J. Cancer</source><year>2018</year><volume>142</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/ijc.31043</pub-id><pub-id pub-id-type="pmid">28940326</pub-id></element-citation></ref><ref id="B5-cancers-16-01191"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cronin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Plevritis</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Fryback</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zelen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mandelblatt</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Yakovlev</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Habbema</surname><given-names>J.D.F.</given-names></name><name name-style="western"><surname>Feuer</surname><given-names>E.J.</given-names></name></person-group><article-title>Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>1784</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050518</pub-id><pub-id pub-id-type="pmid">16251534</pub-id></element-citation></ref><ref id="B6-cancers-16-01191"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer Statistics, 2022</article-title><source>CA Cancer J. Clin.</source><year>2022</year><volume>72</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21708</pub-id><pub-id pub-id-type="pmid">35020204</pub-id></element-citation></ref><ref id="B7-cancers-16-01191"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Luccio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirotsu</surname><given-names>T.C.</given-names></name></person-group><article-title>Elegans as a Powerful Tool for Cancer Screening</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>2371</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10102371</pub-id><pub-id pub-id-type="pmid">36289633</pub-id><pub-id pub-id-type="pmcid">PMC9598459</pub-id></element-citation></ref><ref id="B8-cancers-16-01191"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barsouk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saginala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aluru</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Rawla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barsouk</surname><given-names>A.</given-names></name></person-group><article-title>US Cancer Screening Recommendations: Developments and the Impact of COVID-19</article-title><source>Med. Sci.</source><year>2022</year><volume>10</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.3390/medsci10010016</pub-id><pub-id pub-id-type="pmid">35323215</pub-id><pub-id pub-id-type="pmcid">PMC8949858</pub-id></element-citation></ref><ref id="B9-cancers-16-01191"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armaroli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Villain</surname><given-names>P.</given-names></name><name name-style="western"><surname>Suonio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Almonte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anttila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atkin</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Dillner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>R.</given-names></name><etal/></person-group><article-title>European Code against Cancer, 4th Edition: Cancer Screening</article-title><source>Cancer Epidemiol.</source><year>2015</year><volume>39</volume><fpage>S139</fpage><lpage>S152</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2015.10.021</pub-id><pub-id pub-id-type="pmid">26596722</pub-id></element-citation></ref><ref id="B10-cancers-16-01191"><label>10.</label><element-citation publication-type="journal"><article-title>US Preventive Services Task Force Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement</article-title><source>JAMA</source><year>2018</year><volume>319</volume><fpage>1901</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.3710</pub-id><pub-id pub-id-type="pmid">29801017</pub-id></element-citation></ref><ref id="B11-cancers-16-01191"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadsworth</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Wessman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bj&#246;rnsson</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Jonsdottir</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kristinsson</surname><given-names>S.Y.</given-names></name></person-group><article-title>The Half-Painted Picture: Reviewing the Mental Health Impacts of Cancer Screening</article-title><source>Medicine</source><year>2022</year><volume>101</volume><fpage>e30479</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000030479</pub-id><pub-id pub-id-type="pmid">36197248</pub-id><pub-id pub-id-type="pmcid">PMC9509034</pub-id></element-citation></ref><ref id="B12-cancers-16-01191"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G.X.</given-names></name><name name-style="western"><surname>Raz</surname><given-names>D.J.</given-names></name></person-group><article-title>Lung Cancer Screening</article-title><source>Cancer Treat. Res.</source><year>2016</year><volume>170</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-40389-2_1</pub-id><pub-id pub-id-type="pmid">27535387</pub-id></element-citation></ref><ref id="B13-cancers-16-01191"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Independent UK Panel on Breast Cancer Screening</collab></person-group><article-title>The Benefits and Harms of Breast Cancer Screening: An Independent Review</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>1778</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61611-0</pub-id><pub-id pub-id-type="pmid">23117178</pub-id></element-citation></ref><ref id="B14-cancers-16-01191"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barry</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>L.H.</given-names></name></person-group><article-title>Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection</article-title><source>Med. Clin. North. Am.</source><year>2017</year><volume>101</volume><fpage>787</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2017.03.009</pub-id><pub-id pub-id-type="pmid">28577627</pub-id></element-citation></ref><ref id="B15-cancers-16-01191"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geneve</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kairys</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bean</surname><given-names>B.</given-names></name><name name-style="western"><surname>Provost</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>R.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>N.</given-names></name></person-group><article-title>Colorectal Cancer Screening</article-title><source>Prim. Care</source><year>2019</year><volume>46</volume><fpage>135</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.pop.2018.11.001</pub-id><pub-id pub-id-type="pmid">30704654</pub-id></element-citation></ref><ref id="B16-cancers-16-01191"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>M.J.</given-names></name></person-group><article-title>Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?</article-title><source>Clin. Chem.</source><year>2001</year><volume>47</volume><fpage>624</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1093/clinchem/47.4.624</pub-id><pub-id pub-id-type="pmid">11274010</pub-id></element-citation></ref><ref id="B17-cancers-16-01191"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahlquist</surname><given-names>D.A.</given-names></name></person-group><article-title>Universal Cancer Screening: Revolutionary, Rational, and Realizable</article-title><source>NPJ Precis. Onc.</source><year>2018</year><volume>2</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1038/s41698-018-0066-x</pub-id><pub-id pub-id-type="pmid">30393772</pub-id><pub-id pub-id-type="pmcid">PMC6206005</pub-id></element-citation></ref><ref id="B18-cancers-16-01191"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito-Rocha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Const&#226;ncio</surname><given-names>V.</given-names></name><name name-style="western"><surname>Henrique</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jer&#243;nimo</surname><given-names>C.</given-names></name></person-group><article-title>Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>935</elocation-id><pub-id pub-id-type="doi">10.3390/cells12060935</pub-id><pub-id pub-id-type="pmid">36980276</pub-id><pub-id pub-id-type="pmcid">PMC10047029</pub-id></element-citation></ref><ref id="B19-cancers-16-01191"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackshaw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Reichert</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kansal</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Ofman</surname><given-names>J.J.</given-names></name></person-group><article-title>Estimating the Population Health Impact of a Multi-Cancer Early Detection Genomic Blood Test to Complement Existing Screening in the US and UK</article-title><source>Br. J. Cancer</source><year>2021</year><volume>125</volume><fpage>1432</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01498-4</pub-id><pub-id pub-id-type="pmid">34426664</pub-id><pub-id pub-id-type="pmcid">PMC8575970</pub-id></element-citation></ref><ref id="B20-cancers-16-01191"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Moleyar-Narayana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ranganathan</surname><given-names>S.</given-names></name></person-group><article-title>Cancer Screening</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><pub-id pub-id-type="pmid">33085285</pub-id></element-citation></ref><ref id="B21-cancers-16-01191"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Issa</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Noureddine</surname><given-names>M.</given-names></name></person-group><article-title>Colorectal Cancer Screening: An Updated Review of the Available Options</article-title><source>World J. Gastroenterol.</source><year>2017</year><volume>23</volume><fpage>5086</fpage><lpage>5096</lpage><pub-id pub-id-type="doi">10.3748/wjg.v23.i28.5086</pub-id><pub-id pub-id-type="pmid">28811705</pub-id><pub-id pub-id-type="pmcid">PMC5537177</pub-id></element-citation></ref><ref id="B22-cancers-16-01191"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bond</surname><given-names>J.H.</given-names></name></person-group><article-title>Fecal Occult Blood Test Screening for Colorectal Cancer</article-title><source>Gastrointest. Endosc. Clin. N. Am.</source><year>2002</year><volume>12</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S1052-5157(03)00054-0</pub-id><pub-id pub-id-type="pmid">11916154</pub-id></element-citation></ref><ref id="B23-cancers-16-01191"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meklin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Syrj&#228;nen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eskelinen</surname><given-names>M.</given-names></name></person-group><article-title>Colorectal Cancer Screening with Traditional and New-Generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests</article-title><source>Anticancer. Res.</source><year>2020</year><volume>40</volume><fpage>575</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.21873/anticanres.13987</pub-id><pub-id pub-id-type="pmid">32014898</pub-id></element-citation></ref><ref id="B24-cancers-16-01191"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nugent</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Demers</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Kliewer</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>C.N.</given-names></name></person-group><article-title>The Reduction in Colorectal Cancer Mortality after Colonoscopy Varies by Site of the Cancer</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>1128</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.06.052</pub-id><pub-id pub-id-type="pmid">20600026</pub-id></element-citation></ref><ref id="B25-cancers-16-01191"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaminski</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Regula</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kraszewska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Polkowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wojciechowska</surname><given-names>U.</given-names></name><name name-style="western"><surname>Didkowska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zwierko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rupinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nowacki</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Butruk</surname><given-names>E.</given-names></name></person-group><article-title>Quality Indicators for Colonoscopy and the Risk of Interval Cancer</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>362</volume><fpage>1795</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0907667</pub-id><pub-id pub-id-type="pmid">20463339</pub-id></element-citation></ref><ref id="B26-cancers-16-01191"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakemeyer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wittau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henne-Bruns</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kornmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lemke</surname><given-names>J.</given-names></name></person-group><article-title>Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer</article-title><source>Diseases</source><year>2021</year><volume>9</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.3390/diseases9010021</pub-id><pub-id pub-id-type="pmid">33802962</pub-id><pub-id pub-id-type="pmcid">PMC8006010</pub-id></element-citation></ref><ref id="B27-cancers-16-01191"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>US Preventive Services Task Force</collab><name name-style="western"><surname>Davidson</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mangione</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cabana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Doubeni</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Krist</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>1965</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.6238</pub-id><pub-id pub-id-type="pmid">34003218</pub-id></element-citation></ref><ref id="B28-cancers-16-01191"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>A.M.D.</given-names></name><name name-style="western"><surname>Fontham</surname><given-names>E.T.H.</given-names></name><name name-style="western"><surname>Church</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Flowers</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>LaMonte</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Etzioni</surname><given-names>R.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Oeffinger</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>Y.-C.T.</given-names></name><etal/></person-group><article-title>Colorectal Cancer Screening for Average-Risk Adults: 2018 Guideline Update from the American Cancer Society</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>250</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.3322/caac.21457</pub-id><pub-id pub-id-type="pmid">29846947</pub-id></element-citation></ref><ref id="B29-cancers-16-01191"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebell</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Thai</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Royalty</surname><given-names>K.J.</given-names></name></person-group><article-title>Cancer Screening Recommendations: An International Comparison of High Income Countries</article-title><source>Public Health Rev.</source><year>2018</year><volume>39</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s40985-018-0080-0</pub-id><pub-id pub-id-type="pmid">29507820</pub-id><pub-id pub-id-type="pmcid">PMC5833039</pub-id></element-citation></ref><ref id="B30-cancers-16-01191"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>R.</given-names></name><name name-style="western"><surname>Syrogiannouli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bissig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bulliard</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Ducros</surname><given-names>C.</given-names></name><name name-style="western"><surname>Del Giovane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zwahlen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Selby</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Ten-Year Changes in Colorectal Cancer Screening in Switzerland: The Swiss Health Interview Survey 2007, 2012 and 2017</article-title><source>Prev. Med. Rep.</source><year>2022</year><volume>27</volume><fpage>101815</fpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2022.101815</pub-id><pub-id pub-id-type="pmid">35656207</pub-id><pub-id pub-id-type="pmcid">PMC9152794</pub-id></element-citation></ref><ref id="B31-cancers-16-01191"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bretthauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#248;berg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wieszczy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalager</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emilsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garborg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rupinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spaander</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bugajski</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>1547</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2208375</pub-id><pub-id pub-id-type="pmid">36214590</pub-id></element-citation></ref><ref id="B32-cancers-16-01191"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmeister</surname><given-names>M.</given-names></name></person-group><article-title>Interim Evaluation of the Colorectal Cancer Screening Programme in the Netherlands</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2022</year><volume>7</volume><fpage>8</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(21)00392-7</pub-id><pub-id pub-id-type="pmid">34822761</pub-id></element-citation></ref><ref id="B33-cancers-16-01191"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diedrich</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krauth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robra</surname><given-names>B.-P.</given-names></name><name name-style="western"><surname>Stahmeyer</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Dreier</surname><given-names>M.</given-names></name></person-group><article-title>General Populations&#8217; Preferences for Colorectal Cancer Screening: Rationale and Protocol for the Discrete Choice Experiment in the SIGMO Study</article-title><source>BMJ Open</source><year>2021</year><volume>11</volume><fpage>e042399</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2020-042399</pub-id><pub-id pub-id-type="pmid">33478964</pub-id><pub-id pub-id-type="pmcid">PMC7825272</pub-id></element-citation></ref><ref id="B34-cancers-16-01191"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saraste</surname><given-names>D.</given-names></name><name name-style="western"><surname>T&#246;rnberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>H.</given-names></name></person-group><article-title>Routine Fecal Occult Blood Screening and Colorectal Cancer Mortality in Sweden</article-title><source>JAMA Netw. Open</source><year>2024</year><volume>7</volume><fpage>e240516</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.0516</pub-id><pub-id pub-id-type="pmid">38411959</pub-id><pub-id pub-id-type="pmcid">PMC10900849</pub-id></element-citation></ref><ref id="B35-cancers-16-01191"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Donoghue</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>K.</given-names></name><name name-style="western"><surname>MacMathuna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Fenlon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morrin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fahy</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.</given-names></name></person-group><article-title>A National Bowel Cancer Screening Programme Using FIT: Achievements and Challenges</article-title><source>Cancer Prev. Res.</source><year>2019</year><volume>12</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-18-0182</pub-id><pub-id pub-id-type="pmid">30514807</pub-id></element-citation></ref><ref id="B36-cancers-16-01191"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gartlehner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schernhammer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lax</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Preusser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bachler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Titzer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kletecka-Pulker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turnher</surname><given-names>H.</given-names></name><name name-style="western"><surname>Siebert</surname><given-names>U.</given-names></name></person-group><article-title>Screening for Colorectal Cancer</article-title><source>Wien. Klin. Wochenschr.</source><year>2023</year><volume>135</volume><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1007/s00508-023-02209-0</pub-id><pub-id pub-id-type="pmid">37256423</pub-id><pub-id pub-id-type="pmcid">PMC10497440</pub-id></element-citation></ref><ref id="B37-cancers-16-01191"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olesen</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>H.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>M.</given-names></name></person-group><article-title>Nationwide Participation in FIT-Based Colorectal Cancer Screening in Denmark during the COVID-19 Pandemic: An Observational Study</article-title><source>eLife</source><year>2023</year><volume>12</volume><fpage>e81808</fpage><pub-id pub-id-type="doi">10.7554/eLife.81808</pub-id><pub-id pub-id-type="pmid">36695411</pub-id><pub-id pub-id-type="pmcid">PMC10202451</pub-id></element-citation></ref><ref id="B38-cancers-16-01191"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Hoeck</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Schutter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Hal</surname><given-names>G.</given-names></name></person-group><article-title>The Impact of a Six-Year Existing Screening Programme Using the Faecal Immunochemical Test in Flanders (Belgium) on Colorectal Cancer Incidence, Mortality and Survival: A Population-Based Study</article-title><source>Int. J. Environ. Res. Public Health</source><year>2023</year><volume>20</volume><elocation-id>1654</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph20021654</pub-id><pub-id pub-id-type="pmid">36674409</pub-id><pub-id pub-id-type="pmcid">PMC9864341</pub-id></element-citation></ref><ref id="B39-cancers-16-01191"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Canadian Task Force on Preventive Health Care</collab></person-group><article-title>Recommendations on Screening for Colorectal Cancer in Primary Care</article-title><source>CMAJ</source><year>2016</year><volume>188</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1503/cmaj.151125</pub-id><pub-id pub-id-type="pmid">26903355</pub-id><pub-id pub-id-type="pmcid">PMC4786388</pub-id></element-citation></ref><ref id="B40-cancers-16-01191"><label>40.</label><element-citation publication-type="webpage"><article-title>Clinical Practice Guidelines for the Prevention, Early Detection, and Management of Colorectal Cancer: Population Screening</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://app.magicapp.org/#/guideline/j1Q1Xj" ext-link-type="uri">https://app.magicapp.org/#/guideline/j1Q1Xj</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-04">(accessed on 4 March 2024)</date-in-citation></element-citation></ref><ref id="B41-cancers-16-01191"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seitz</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Lapalus</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arlotto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gentile</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ettori</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Grandval</surname><given-names>P.</given-names></name><name name-style="western"><surname>Delasalle</surname><given-names>P.</given-names></name></person-group><article-title>Colorectal Cancer Screening by Fecal Immunochemical Test or Colonoscopy in France: How Many People Are Actually Covered? Focus on the Provence-Alpes-C&#244;te d&#8217;Azur Region</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2022</year><volume>34</volume><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000002338</pub-id><pub-id pub-id-type="pmid">34882643</pub-id><pub-id pub-id-type="pmcid">PMC8876435</pub-id></element-citation></ref><ref id="B42-cancers-16-01191"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimoda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sekiguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tamai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hotta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Misawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Colonoscopy Screening and Surveillance Guidelines</article-title><source>Dig. Endosc.</source><year>2021</year><volume>33</volume><fpage>486</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1111/den.13972</pub-id><pub-id pub-id-type="pmid">33713493</pub-id></element-citation></ref><ref id="B43-cancers-16-01191"><label>43.</label><element-citation publication-type="gov"><article-title>Bowel Cancer-UK National Screening Committee (UK NSC)-GOV.UK</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://view-health-screening-recommendations.service.gov.uk/bowel-cancer/" ext-link-type="uri">https://view-health-screening-recommendations.service.gov.uk/bowel-cancer/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-04">(accessed on 4 March 2024)</date-in-citation></element-citation></ref><ref id="B44-cancers-16-01191"><label>44.</label><element-citation publication-type="gov"><article-title>Clinical Practice Guidelines for Bowel Screening in New Zealand&#8212;Health New Zealand|Te Whatu Ora</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tewhatuora.govt.nz/publications/clinical-practice-guidelines-for-bowel-screening-in-new-zealand/" ext-link-type="uri">https://www.tewhatuora.govt.nz/publications/clinical-practice-guidelines-for-bowel-screening-in-new-zealand/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-04">(accessed on 4 March 2024)</date-in-citation></element-citation></ref><ref id="B45-cancers-16-01191"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bucchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baldacchini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ravaioli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giuliani</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vattiato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zamagni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Giorgi Rossi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Campari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Canuti</surname><given-names>D.</given-names></name><etal/></person-group><article-title>How a Faecal Immunochemical Test Screening Programme Changes Annual Colorectal Cancer Incidence Rates: An Italian Intention-to-Screen Study</article-title><source>Br. J. Cancer</source><year>2022</year><volume>127</volume><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01813-7</pub-id><pub-id pub-id-type="pmid">35444286</pub-id><pub-id pub-id-type="pmcid">PMC9345854</pub-id></element-citation></ref><ref id="B46-cancers-16-01191"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nouni-Garc&#237;a</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lara-L&#243;pez</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Carratal&#225;-Munuera</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gil-Guill&#233;n</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>L&#243;pez-Pineda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orozco-Beltr&#225;n</surname><given-names>D.</given-names></name><name name-style="western"><surname>Quesada</surname><given-names>J.A.</given-names></name></person-group><article-title>Factors Associated with Colorectal Cancer Screening in Spain: Results of the 2017 National Health Survey</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>5460</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19095460</pub-id><pub-id pub-id-type="pmid">35564855</pub-id><pub-id pub-id-type="pmcid">PMC9100170</pub-id></element-citation></ref><ref id="B47-cancers-16-01191"><label>47.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Budh</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Sapra</surname><given-names>A.</given-names></name></person-group><article-title>Breast Cancer Screening</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><pub-id pub-id-type="pmid">32310510</pub-id></element-citation></ref><ref id="B48-cancers-16-01191"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Autier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boniol</surname><given-names>M.</given-names></name></person-group><article-title>Mammography Screening: A Major Issue in Medicine</article-title><source>Eur. J. Cancer</source><year>2018</year><volume>90</volume><fpage>34</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2017.11.002</pub-id><pub-id pub-id-type="pmid">29272783</pub-id></element-citation></ref><ref id="B49-cancers-16-01191"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>B.-I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-J.</given-names></name></person-group><article-title>Use of CA15-3 for Screening Breast Cancer: An Antibody-Lectin Sandwich Assay for Detecting Glycosylation of CA15-3 in Sera</article-title><source>Oncol. Rep.</source><year>2018</year><volume>40</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6433</pub-id><pub-id pub-id-type="pmid">29749490</pub-id><pub-id pub-id-type="pmcid">PMC6059737</pub-id></element-citation></ref><ref id="B50-cancers-16-01191"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Evoy</surname><given-names>D.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>E.W.</given-names></name></person-group><article-title>CA 15-3: Uses and Limitation as a Biomarker for Breast Cancer</article-title><source>Clin. Chim. Acta</source><year>2010</year><volume>411</volume><fpage>1869</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2010.08.039</pub-id><pub-id pub-id-type="pmid">20816948</pub-id></element-citation></ref><ref id="B51-cancers-16-01191"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davisson</surname><given-names>L.</given-names></name></person-group><article-title>USPSTF Breast Cancer Screening Guidelines</article-title><source>W. V. Med. J.</source><year>2016</year><volume>112</volume><fpage>29</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">29368825</pub-id></element-citation></ref><ref id="B52-cancers-16-01191"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oeffinger</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Fontham</surname><given-names>E.T.H.</given-names></name><name name-style="western"><surname>Etzioni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Herzig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michaelson</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>Y.-C.T.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Church</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Flowers</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>LaMonte</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update from the American Cancer Society</article-title><source>JAMA</source><year>2015</year><volume>314</volume><fpage>1599</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.12783</pub-id><pub-id pub-id-type="pmid">26501536</pub-id><pub-id pub-id-type="pmcid">PMC4831582</pub-id></element-citation></ref><ref id="B53-cancers-16-01191"><label>53.</label><element-citation publication-type="webpage"><article-title>Draft Recommendation: Breast Cancer: Screening|United States Preventive Services Taskforce</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/breast-cancer-screening-adults#bcei-recommendation-title-area" ext-link-type="uri">https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/breast-cancer-screening-adults#bcei-recommendation-title-area</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-04">(accessed on 4 March 2024)</date-in-citation></element-citation></ref><ref id="B54-cancers-16-01191"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saslow</surname><given-names>D.</given-names></name><name name-style="western"><surname>Boetes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>W.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pisano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schnall</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sener</surname><given-names>S.</given-names></name><etal/></person-group><article-title>American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography</article-title><source>CA Cancer J. Clin.</source><year>2007</year><volume>57</volume><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.3322/canjclin.57.2.75</pub-id><pub-id pub-id-type="pmid">17392385</pub-id></element-citation></ref><ref id="B55-cancers-16-01191"><label>55.</label><element-citation publication-type="webpage"><article-title>Breast Cancer Risk Assessment and Screening in Average-Risk Women</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/07/breast-cancer-risk-assessment-and-screening-in-average-risk-women" ext-link-type="uri">https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/07/breast-cancer-risk-assessment-and-screening-in-average-risk-women</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-04">(accessed on 4 March 2024)</date-in-citation></element-citation></ref><ref id="B56-cancers-16-01191"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monticciolo</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Malak</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Friedewald</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Eby</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Newell</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Moy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Destounis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J.W.T.</given-names></name><name name-style="western"><surname>Hendrick</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Smetherman</surname><given-names>D.</given-names></name></person-group><article-title>Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging</article-title><source>J. Am. Coll. Radiol.</source><year>2021</year><volume>18</volume><fpage>1280</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.jacr.2021.04.021</pub-id><pub-id pub-id-type="pmid">34154984</pub-id></element-citation></ref><ref id="B57-cancers-16-01191"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monticciolo</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Newell</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Moy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Destounis</surname><given-names>S.V.</given-names></name></person-group><article-title>Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations from the ACR</article-title><source>J. Am. Coll. Radiol.</source><year>2023</year><volume>20</volume><fpage>902</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1016/j.jacr.2023.04.002</pub-id><pub-id pub-id-type="pmid">37150275</pub-id></element-citation></ref><ref id="B58-cancers-16-01191"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vounatsou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Th&#252;rlimann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Probst-Hensch</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rothermundt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ess</surname><given-names>S.</given-names></name></person-group><article-title>Impact of Mammography Screening Programmes on Breast Cancer Mortality in Switzerland, a Country with Different Regional Screening Policies</article-title><source>BMJ Open</source><year>2018</year><volume>8</volume><fpage>e017806</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2017-017806</pub-id><pub-id pub-id-type="pmid">29540406</pub-id><pub-id pub-id-type="pmcid">PMC5857683</pub-id></element-citation></ref><ref id="B59-cancers-16-01191"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bringedal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fretheim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nilsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Isaksson R&#248;</surname><given-names>K.</given-names></name></person-group><article-title>Do You Recommend Cancer Screening to Your Patients? A Cross-Sectional Study of Norwegian Doctors</article-title><source>BMJ Open</source><year>2019</year><volume>9</volume><fpage>e029739</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2019-029739</pub-id><pub-id pub-id-type="pmid">31473617</pub-id><pub-id pub-id-type="pmcid">PMC6720551</pub-id></element-citation></ref><ref id="B60-cancers-16-01191"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kregting</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Olthof</surname><given-names>E.M.G.</given-names></name><name name-style="western"><surname>Breekveldt</surname><given-names>E.C.H.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Heijnsdijk</surname><given-names>E.A.M.</given-names></name><name name-style="western"><surname>Toes-Zoutendijk</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Koning</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Van Ravesteyn</surname><given-names>N.T.</given-names></name></person-group><article-title>Concurrent Participation in Breast, Cervical, and Colorectal Cancer Screening in the Netherlands</article-title><source>Eur. J. Cancer</source><year>2022</year><volume>175</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.08.018</pub-id><pub-id pub-id-type="pmid">36126478</pub-id></element-citation></ref><ref id="B61-cancers-16-01191"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Langner</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zeeb</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haug</surname><given-names>U.</given-names></name></person-group><article-title>German Mammography Screening Program: Adherence, Characteristics of (Non-)Participants and Utilization of Non-Screening Mammography&#8212;A Longitudinal Analysis</article-title><source>BMC Public Health</source><year>2023</year><volume>23</volume><elocation-id>1678</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-023-16589-5</pub-id><pub-id pub-id-type="pmid">37653487</pub-id><pub-id pub-id-type="pmcid">PMC10469853</pub-id></element-citation></ref><ref id="B62-cancers-16-01191"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagerlund</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#197;kesson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zackrisson</surname><given-names>S.</given-names></name></person-group><article-title>Population-Based Mammography Screening Attendance in Sweden 2017&#8211;2018: A Cross-Sectional Register Study to Assess the Impact of Sociodemographic Factors</article-title><source>Breast</source><year>2021</year><volume>59</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2021.05.011</pub-id><pub-id pub-id-type="pmid">34118780</pub-id><pub-id pub-id-type="pmcid">PMC8207312</pub-id></element-citation></ref><ref id="B63-cancers-16-01191"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;Donovan</surname><given-names>A.</given-names></name></person-group><article-title>Factors Associated with Breast Cancer Mammography Screening and Breast Self-Examination in Irish Women: Results from the Irish Longitudinal Study on Ageing (TILDA)</article-title><source>Acta Oncol.</source><year>2022</year><volume>61</volume><fpage>1301</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1080/0284186X.2022.2143277</pub-id><pub-id pub-id-type="pmid">36369703</pub-id></element-citation></ref><ref id="B64-cancers-16-01191"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiller-Fruehwirth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jahn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Einzinger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zauner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Urach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Siebert</surname><given-names>U.</given-names></name></person-group><article-title>The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria</article-title><source>Value Health</source><year>2017</year><volume>20</volume><fpage>1048</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2017.04.009</pub-id><pub-id pub-id-type="pmid">28964436</pub-id></element-citation></ref><ref id="B65-cancers-16-01191"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynge</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bak</surname><given-names>M.</given-names></name><name name-style="western"><surname>von Euler-Chelpin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kroman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lernevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mogensen</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wronecki</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Vejborg</surname><given-names>I.</given-names></name></person-group><article-title>Outcome of Breast Cancer Screening in Denmark</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><elocation-id>897</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3929-6</pub-id><pub-id pub-id-type="pmid">29282034</pub-id><pub-id pub-id-type="pmcid">PMC5745763</pub-id></element-citation></ref><ref id="B66-cancers-16-01191"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Troeyer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Silversmit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rosskamp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Truyen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Van Herck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kellen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hendrickx</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rummens</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The Effect of the Flemish Breast Cancer Screening Program on Breast Cancer-Specific Mortality: A Case-Referent Study</article-title><source>Cancer Epidemiol.</source><year>2023</year><volume>82</volume><fpage>102320</fpage><pub-id pub-id-type="doi">10.1016/j.canep.2022.102320</pub-id><pub-id pub-id-type="pmid">36608495</pub-id></element-citation></ref><ref id="B67-cancers-16-01191"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klarenbach</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sims-Jones</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Th&#233;riault</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tonelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doull</surname><given-names>M.</given-names></name><name name-style="western"><surname>Courage</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Thombs</surname><given-names>B.D.</given-names></name></person-group><article-title>Recommendations on Screening for Breast Cancer in Women Aged 40&#8211;74 Years Who Are Not at Increased Risk for Breast Cancer</article-title><source>CMAJ</source><year>2018</year><volume>190</volume><fpage>E1441</fpage><lpage>E1451</lpage><pub-id pub-id-type="doi">10.1503/cmaj.180463</pub-id><pub-id pub-id-type="pmid">30530611</pub-id><pub-id pub-id-type="pmcid">PMC6279444</pub-id></element-citation></ref><ref id="B68-cancers-16-01191"><label>68.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Australian Institute of Health and Welfare</collab></person-group><article-title>BreastScreen Australia Monitoring Report</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.breastcheck.ie/_fileupload/documents/BC-PR-PM-12-Rev0-BreastCheck-Programme-Report_2018_and_2019.pdf" ext-link-type="uri">https://www.breastcheck.ie/_fileupload/documents/BC-PR-PM-12-Rev0-BreastCheck-Programme-Report_2018_and_2019.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-04">(accessed on 4 March 2024)</date-in-citation></element-citation></ref><ref id="B69-cancers-16-01191"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nickson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Velentzis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Houssami</surname><given-names>N.</given-names></name></person-group><article-title>Improving Breast Cancer Screening in Australia: A Public Health Perspective</article-title><source>Public Health Res. Pract.</source><year>2019</year><volume>29</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.17061/phrp2921911</pub-id><pub-id pub-id-type="pmid">31384884</pub-id></element-citation></ref><ref id="B70-cancers-16-01191"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seradour</surname><given-names>B.</given-names></name></person-group><article-title>The French breast cancer screening program in 2022: Ensuring progress</article-title><source>Bull Cancer</source><year>2022</year><volume>109</volume><fpage>756</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/j.bulcan.2022.02.010</pub-id><pub-id pub-id-type="pmid">35504758</pub-id></element-citation></ref><ref id="B71-cancers-16-01191"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uematsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Izumori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>W.K.</given-names></name></person-group><article-title>Overcoming the Limitations of Screening Mammography in Japan and Korea: A Paradigm Shift to Personalized Breast Cancer Screening Based on Ultrasonography</article-title><source>Ultrasonography</source><year>2023</year><volume>42</volume><fpage>508</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.14366/usg.23047</pub-id><pub-id pub-id-type="pmid">37697823</pub-id><pub-id pub-id-type="pmcid">PMC10555688</pub-id></element-citation></ref><ref id="B72-cancers-16-01191"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Njor</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Hein&#228;vaara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stefansd&#243;ttir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nyg&#229;rd</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gu&#240;mundsd&#243;ttir</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leivonen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>S.</given-names></name><name name-style="western"><surname>S&#248;borg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hofvind</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Differences in Mammography Screening Attendance among Non-Western Immigrants in Denmark, Finland, Iceland and Norway</article-title><source>Prev. Med. Rep.</source><year>2023</year><volume>36</volume><fpage>102516</fpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2023.102516</pub-id><pub-id pub-id-type="pmid">38116274</pub-id><pub-id pub-id-type="pmcid">PMC10728433</pub-id></element-citation></ref><ref id="B73-cancers-16-01191"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor-Phillips</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seedat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kijauskaite</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Halligan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Given-Wilson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Denniston</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Glocker</surname><given-names>B.</given-names></name><etal/></person-group><article-title>UK National Screening Committee&#8217;s Approach to Reviewing Evidence on Artificial Intelligence in Breast Cancer Screening</article-title><source>Lancet Digit. Health</source><year>2022</year><volume>4</volume><fpage>e558</fpage><lpage>e565</lpage><pub-id pub-id-type="doi">10.1016/S2589-7500(22)00088-7</pub-id><pub-id pub-id-type="pmid">35750402</pub-id></element-citation></ref><ref id="B74-cancers-16-01191"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sexton</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wharton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Amoyal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morrell</surname><given-names>S.</given-names></name></person-group><article-title>Breast Cancer Mortality and Screening Mammography in New Zealand: Incidence-Based and Aggregate Analyses</article-title><source>J. Med. Screen</source><year>2019</year><volume>26</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1177/0969141318776039</pub-id><pub-id pub-id-type="pmid">29895225</pub-id></element-citation></ref><ref id="B75-cancers-16-01191"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelullo</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Cantore</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lisciotto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Giuseppe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pavia</surname><given-names>M.</given-names></name></person-group><article-title>Organized Breast and Cervical Cancer Screening: Attendance and Determinants in Southern Italy</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>1578</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13071578</pub-id><pub-id pub-id-type="pmid">33808101</pub-id><pub-id pub-id-type="pmcid">PMC8036794</pub-id></element-citation></ref><ref id="B76-cancers-16-01191"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portero de la Cruz</surname><given-names>S.</given-names></name><name name-style="western"><surname>B&#233;jar</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Cebrino</surname><given-names>J.</given-names></name></person-group><article-title>Temporal Evolution and Associated Factors of Adherence to Mammography Screening among Women in Spain: Results from Two National Health Surveys (2017&#8211;2020)</article-title><source>Healthcare</source><year>2023</year><volume>11</volume><elocation-id>2934</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare11222934</pub-id><pub-id pub-id-type="pmid">37998426</pub-id><pub-id pub-id-type="pmcid">PMC10671473</pub-id></element-citation></ref><ref id="B77-cancers-16-01191"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Djulbegovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cleves</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agoritsas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dahm</surname><given-names>P.</given-names></name></person-group><article-title>Prostate Cancer Screening with Prostate-Specific Antigen (PSA) Test: A Systematic Review and Meta-Analysis</article-title><source>BMJ</source><year>2018</year><volume>362</volume><fpage>k3519</fpage><pub-id pub-id-type="doi">10.1136/bmj.k3519</pub-id><pub-id pub-id-type="pmid">30185521</pub-id><pub-id pub-id-type="pmcid">PMC6283370</pub-id></element-citation></ref><ref id="B78-cancers-16-01191"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balk</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Bubley</surname><given-names>G.J.</given-names></name></person-group><article-title>Biology of Prostate-Specific Antigen</article-title><source>JCO</source><year>2003</year><volume>21</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.02.083</pub-id><pub-id pub-id-type="pmid">12525533</pub-id></element-citation></ref><ref id="B79-cancers-16-01191"><label>79.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>S.W.</given-names></name></person-group><article-title>Prostate Specific Antigen</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><pub-id pub-id-type="pmid">32491427</pub-id></element-citation></ref><ref id="B80-cancers-16-01191"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>London</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fazio-Eynullayeva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Palchuk</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sankey</surname><given-names>P.</given-names></name><name name-style="western"><surname>McNair</surname><given-names>C.</given-names></name></person-group><article-title>Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters</article-title><source>JCO Clin. Cancer Inform.</source><year>2020</year><fpage>657</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1200/CCI.20.00068</pub-id><pub-id pub-id-type="pmid">32716647</pub-id><pub-id pub-id-type="pmcid">PMC7444638</pub-id></element-citation></ref><ref id="B81-cancers-16-01191"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>J.D.</given-names></name></person-group><article-title>Impact of the Evolving United States Preventative Services Task Force Policy Statements on Incidence and Distribution of Prostate Cancer over 15 Years in a Statewide Cancer Registry</article-title><source>Prostate Int.</source><year>2021</year><volume>9</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.prnil.2020.06.002</pub-id><pub-id pub-id-type="pmid">33912509</pub-id><pub-id pub-id-type="pmcid">PMC8053697</pub-id></element-citation></ref><ref id="B82-cancers-16-01191"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Lung Screening Trial Research Team</collab><name name-style="western"><surname>Church</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Black</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Aberle</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Clingan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fagerstrom</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Gareen</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Gierada</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>1980</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209120</pub-id><pub-id pub-id-type="pmid">23697514</pub-id><pub-id pub-id-type="pmcid">PMC3762603</pub-id></element-citation></ref><ref id="B83-cancers-16-01191"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pastorino</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sverzellati</surname><given-names>N.</given-names></name></person-group><article-title>Lung Cancer Screening with Low-Dose CT in Europe: Strength and Weakness of Diverse Independent Screening Trials</article-title><source>Clin. Radiol.</source><year>2017</year><volume>72</volume><fpage>389</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.crad.2016.12.021</pub-id><pub-id pub-id-type="pmid">28168954</pub-id></element-citation></ref><ref id="B84-cancers-16-01191"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amicizia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piazza</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Marchini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Astengo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grammatico</surname><given-names>F.</given-names></name><name name-style="western"><surname>Battaglini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schenone</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sticchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lavieri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di Silverio</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Systematic Review of Lung Cancer Screening: Advancements and Strategies for Implementation</article-title><source>Healthcare</source><year>2023</year><volume>11</volume><elocation-id>2085</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare11142085</pub-id><pub-id pub-id-type="pmid">37510525</pub-id><pub-id pub-id-type="pmcid">PMC10379173</pub-id></element-citation></ref><ref id="B85-cancers-16-01191"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartlett</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Callister</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>A.</given-names></name></person-group><article-title>False-Negative Results in Lung Cancer Screening-Evidence and Controversies</article-title><source>J. Thorac. Oncol.</source><year>2021</year><volume>16</volume><fpage>912</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2021.01.1607</pub-id><pub-id pub-id-type="pmid">33545386</pub-id></element-citation></ref><ref id="B86-cancers-16-01191"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colson</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Shepard</surname><given-names>J.-A.O.</given-names></name><name name-style="western"><surname>Lennes</surname><given-names>I.T.</given-names></name></person-group><article-title>New USPSTF Guidelines for Lung Cancer Screening: Better but Not Enough</article-title><source>JAMA Surg.</source><year>2021</year><volume>156</volume><fpage>513</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2021.0242</pub-id><pub-id pub-id-type="pmid">33687427</pub-id></element-citation></ref><ref id="B87-cancers-16-01191"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>A.M.D.</given-names></name><name name-style="western"><surname>Oeffinger</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>T.Y.-C.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Church</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Fontham</surname><given-names>E.T.H.</given-names></name><name name-style="western"><surname>Elkin</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Etzioni</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>R.B.</given-names></name><etal/></person-group><article-title>Screening for Lung Cancer: 2023 Guideline Update from the American Cancer Society</article-title><source>CA Cancer J. Clin.</source><year>2024</year><volume>74</volume><fpage>50</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.3322/caac.21811</pub-id><pub-id pub-id-type="pmid">37909877</pub-id></element-citation></ref><ref id="B88-cancers-16-01191"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>E.E.L.</given-names></name><name name-style="western"><surname>Zielonke</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anttila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Segnan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vok&#243;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ivanu&#353;</surname><given-names>U.</given-names></name><name name-style="western"><surname>McKee</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>de Kok</surname><given-names>I.M.C.M.</given-names></name><etal/></person-group><article-title>Effect of Organised Cervical Cancer Screening on Cervical Cancer Mortality in Europe: A Systematic Review</article-title><source>Eur. J. Cancer</source><year>2020</year><volume>127</volume><fpage>207</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.12.013</pub-id><pub-id pub-id-type="pmid">31980322</pub-id></element-citation></ref><ref id="B89-cancers-16-01191"><label>89.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Melnikow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Burda</surname><given-names>B.U.</given-names></name><name name-style="western"><surname>Senger</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Durbin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soulsby</surname><given-names>M.A.</given-names></name></person-group><article-title>Screening for Cervical Cancer with High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the U.S. Preventive Services Task Force; U.S</article-title><source>Preventive Services Task Force Evidence Syntheses, Formerly Systematic Evidence Reviews</source><publisher-name>Agency for Healthcare Research and Quality</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2018</year><pub-id pub-id-type="pmid">30256575</pub-id></element-citation></ref><ref id="B90-cancers-16-01191"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontham</surname><given-names>E.T.H.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>A.M.D.</given-names></name><name name-style="western"><surname>Church</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Etzioni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Flowers</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Herzig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Oeffinger</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>Y.-C.T.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>L.C.</given-names></name><etal/></person-group><article-title>Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society</article-title><source>CA Cancer J. Clin.</source><year>2020</year><volume>70</volume><fpage>321</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.3322/caac.21628</pub-id><pub-id pub-id-type="pmid">32729638</pub-id></element-citation></ref><ref id="B91-cancers-16-01191"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>US Preventive Services Task Force</collab><name name-style="western"><surname>Curry</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Krist</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Owens</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Doubeni</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Epling</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kemper</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement</article-title><source>JAMA</source><year>2018</year><volume>320</volume><fpage>674</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1097/01.ogx.0000549540.69362.81</pub-id><pub-id pub-id-type="pmid">30140884</pub-id></element-citation></ref><ref id="B92-cancers-16-01191"><label>92.</label><element-citation publication-type="webpage"><article-title>Updated Cervical Cancer Screening Guidelines</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines" ext-link-type="uri">https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-05">(accessed on 5 March 2024)</date-in-citation></element-citation></ref><ref id="B93-cancers-16-01191"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tirri</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Petignat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jacot-Guillarmod</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kind</surname><given-names>A.B.</given-names></name></person-group><article-title>Recommandations pour la pr&#233;vention du cancer du col de l&#8217;ut&#233;rus</article-title><source>Avis, D&#8217;expert</source><year>2018</year><volume>50</volume><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="B94-cancers-16-01191"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bj&#248;rge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Enges&#230;ter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Skare</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Trop&#233;</surname><given-names>A.</given-names></name></person-group><article-title>CervicalScreen Norway&#8212;A Screening Programme in Transition</article-title><source>Nor. J. Epidemiol.</source><year>2022</year><volume>30</volume><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.5324/nje.v30i1-2.4978</pub-id></element-citation></ref><ref id="B95-cancers-16-01191"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gro&#223;mann</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Napierala</surname><given-names>H.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>W.J.</given-names></name></person-group><article-title>Differences in Breast and Cervical Cancer Screening between West and East Germany: A Secondary Analysis of a German Nationwide Health Survey</article-title><source>BMC Public Health</source><year>2023</year><volume>23</volume><elocation-id>1931</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-023-16849-4</pub-id><pub-id pub-id-type="pmid">37798695</pub-id><pub-id pub-id-type="pmcid">PMC10557316</pub-id></element-citation></ref><ref id="B96-cancers-16-01191"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Holleczek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Henes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Juhasz-B&#246;ss</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wallwiener</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neis</surname><given-names>K.J.</given-names></name></person-group><article-title>Proposal for a Descriptive and Differentiated Presentation of the Longitudinal Impact of the New Organized Cancer Screening Guideline and HPV Vaccination in Germany</article-title><source>Arch. Gynecol. Obstet.</source><year>2022</year><volume>307</volume><fpage>1125</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1007/s00404-022-06747-2</pub-id><pub-id pub-id-type="pmid">36053348</pub-id><pub-id pub-id-type="pmcid">PMC10023646</pub-id></element-citation></ref><ref id="B97-cancers-16-01191"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Arc&#224;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>K.</given-names></name><name name-style="western"><surname>Houwing</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kothari</surname><given-names>S.</given-names></name></person-group><article-title>Cervical Cancer Screening Guidelines and Screening Practices in 11 Countries: A Systematic Literature Review</article-title><source>Prev. Med. Rep.</source><year>2022</year><volume>28</volume><fpage>101813</fpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2022.101813</pub-id><pub-id pub-id-type="pmid">35637896</pub-id><pub-id pub-id-type="pmcid">PMC9142642</pub-id></element-citation></ref><ref id="B98-cancers-16-01191"><label>98.</label><element-citation publication-type="webpage"><article-title>Cervical Cancer Screening|Irish Cancer Society</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.ie/cancer-information-and-support/cancer-types/cervical-cancer/cervical-cancer-screening" ext-link-type="uri">https://www.cancer.ie/cancer-information-and-support/cancer-types/cervical-cancer/cervical-cancer-screening</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-05">(accessed on 5 March 2024)</date-in-citation></element-citation></ref><ref id="B99-cancers-16-01191"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brzoska</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wahidie</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yilmaz-Aslan</surname><given-names>Y.</given-names></name></person-group><article-title>An Intersectional Perspective on the Utilization of Cervical Cancer Screening among Migrants. A Cross-Sectional Analysis of Survey Data from Austria</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>6082</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13236082</pub-id><pub-id pub-id-type="pmid">34885190</pub-id><pub-id pub-id-type="pmcid">PMC8657384</pub-id></element-citation></ref><ref id="B100-cancers-16-01191"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonde</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schroll</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kj</surname><given-names>B.</given-names></name></person-group><article-title>Differentieret implementering af HPV-baseret screening i dansk livmoderhalskr&#230;ftscreening</article-title><source>Ugeskr. L&#230;ger</source><year>2022</year><volume>184</volume><fpage>V04210327</fpage></element-citation></ref><ref id="B101-cancers-16-01191"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olesen</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>H.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Waldstr&#248;m</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>B.</given-names></name></person-group><article-title>Participation in the Nationwide Cervical Cancer Screening Programme in Denmark during the COVID-19 Pandemic: An Observational Study</article-title><source>eLife</source><year>2023</year><volume>12</volume><fpage>e81522</fpage><pub-id pub-id-type="doi">10.7554/eLife.81522</pub-id><pub-id pub-id-type="pmid">36661213</pub-id><pub-id pub-id-type="pmcid">PMC9904756</pub-id></element-citation></ref><ref id="B102-cancers-16-01191"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dombrowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bourgain</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meiwald</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pinsent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weynand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Huntington</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Bogers</surname><given-names>J.</given-names></name><etal/></person-group><article-title>An Economic Evaluation of Two Cervical Screening Algorithms in Belgium: HR-HPV Primary Compared to HR-HPV and Liquid-Based Cytology (LBC) Co-Testing</article-title><source>Eur. J. Cancer Prev.</source><year>2023</year><volume>10</volume><fpage>1097</fpage><pub-id pub-id-type="doi">10.1097/CEJ.0000000000000856</pub-id><pub-id pub-id-type="pmcid">PMC10965122</pub-id><pub-id pub-id-type="pmid">37933867</pub-id></element-citation></ref><ref id="B103-cancers-16-01191"><label>103.</label><element-citation publication-type="journal"><article-title>Canadian Task Force on Preventive Health Care Recommendations on Screening for Cervical Cancer</article-title><source>CMAJ</source><year>2013</year><volume>185</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1503/cmaj.121505</pub-id><pub-id pub-id-type="pmid">23297138</pub-id><pub-id pub-id-type="pmcid">PMC3537778</pub-id></element-citation></ref><ref id="B104-cancers-16-01191"><label>104.</label><element-citation publication-type="webpage"><article-title>Cervical Cancer Screening in Australia and New Zealand</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ranzcog.edu.au/wp-content/uploads/2022/05/Cervical-cancer-screening-in-Australia-and-New-Zealand-C-Gyn-19-Amended-July-2020.pdf" ext-link-type="uri">https://ranzcog.edu.au/wp-content/uploads/2022/05/Cervical-cancer-screening-in-Australia-and-New-Zealand-C-Gyn-19-Amended-July-2020.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-05">(accessed on 5 March 2024)</date-in-citation></element-citation></ref><ref id="B105-cancers-16-01191"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamers</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Poulli&#233;</surname><given-names>A.-I.</given-names></name><name name-style="western"><surname>Arbyn</surname><given-names>M.</given-names></name></person-group><article-title>Updated Evidence-Based Recommendations for Cervical Cancer Screening in France</article-title><source>Eur. J. Cancer Prev.</source><year>2022</year><volume>31</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1097/CEJ.0000000000000701</pub-id><pub-id pub-id-type="pmid">34191754</pub-id><pub-id pub-id-type="pmcid">PMC8974187</pub-id></element-citation></ref><ref id="B106-cancers-16-01191"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>E.</given-names></name><name name-style="western"><surname>Katanoda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hocking</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Brotherton</surname><given-names>J.M.L.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>J.J.</given-names></name></person-group><article-title>The Impact of Alternate HPV Vaccination and Cervical Screening Strategies in Japan: A Cost-Effectiveness Analysis</article-title><source>Lancet Reg. Health&#8212;West. Pac.</source><year>2024</year><volume>44</volume><fpage>101018</fpage><pub-id pub-id-type="doi">10.1016/j.lanwpc.2024.101018</pub-id><pub-id pub-id-type="pmid">38404421</pub-id><pub-id pub-id-type="pmcid">PMC10885559</pub-id></element-citation></ref><ref id="B107-cancers-16-01191"><label>107.</label><element-citation publication-type="gov"><article-title>Cervical Cancer&#8212;UK National Screening Committee (UK NSC)&#8212;GOV.UK</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://view-health-screening-recommendations.service.gov.uk/cervical-cancer/" ext-link-type="uri">https://view-health-screening-recommendations.service.gov.uk/cervical-cancer/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-05">(accessed on 5 March 2024)</date-in-citation></element-citation></ref><ref id="B108-cancers-16-01191"><label>108.</label><element-citation publication-type="webpage"><article-title>Finland: Human Papillomavirus and Related Cancers, Fact Sheet 2023. <italic toggle="yes">Fact Sheet</italic></article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hpvcentre.net/statistics/reports/FIN_FS.pdf" ext-link-type="uri">https://hpvcentre.net/statistics/reports/FIN_FS.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-05">(accessed on 5 March 2024)</date-in-citation></element-citation></ref><ref id="B109-cancers-16-01191"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portero de la Cruz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cebrino</surname><given-names>J.</given-names></name></person-group><article-title>Trends and Determinants in Uptake of Cervical Cancer Screening in Spain: An Analysis of National Surveys from 2017 and 2020</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>2481</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14102481</pub-id><pub-id pub-id-type="pmid">35626086</pub-id><pub-id pub-id-type="pmcid">PMC9140061</pub-id></element-citation></ref><ref id="B110-cancers-16-01191"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warnakulasuriya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>A.R.</given-names></name></person-group><article-title>Oral Cancer Screening: Past, Present, and Future</article-title><source>J. Dent. Res.</source><year>2021</year><volume>100</volume><fpage>1313</fpage><lpage>1320</lpage><pub-id pub-id-type="doi">10.1177/00220345211014795</pub-id><pub-id pub-id-type="pmid">34036828</pub-id><pub-id pub-id-type="pmcid">PMC8529297</pub-id></element-citation></ref><ref id="B111-cancers-16-01191"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Warnakulasuriya</surname><given-names>S.</given-names></name></person-group><article-title>Screening for Oral Cancer: Future Prospects, Research and Policy Development for Asia</article-title><source>Oral Oncol.</source><year>2020</year><volume>105</volume><fpage>104632</fpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2020.104632</pub-id><pub-id pub-id-type="pmid">32315954</pub-id></element-citation></ref><ref id="B112-cancers-16-01191"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sankaranarayanan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramadas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muwonge</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Anju</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>B.</given-names></name></person-group><article-title>Long Term Effect of Visual Screening on Oral Cancer Incidence and Mortality in a Randomized Trial in Kerala, India</article-title><source>Oral Oncol.</source><year>2013</year><volume>49</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2012.11.004</pub-id><pub-id pub-id-type="pmid">23265945</pub-id></element-citation></ref><ref id="B113-cancers-16-01191"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>M.F.A.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>M.C.M.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bruzinga</surname><given-names>F.F.B.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Grossmann</surname><given-names>S.d.M.C.</given-names></name><name name-style="western"><surname>de Ara&#250;jo</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Souto</surname><given-names>G.R.</given-names></name></person-group><article-title>Assessment of Screening Programs as a Strategy for Early Detection of Oral Cancer: A Systematic Review</article-title><source>Oral Oncol.</source><year>2022</year><volume>130</volume><fpage>105936</fpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2022.105936</pub-id><pub-id pub-id-type="pmid">35662028</pub-id></element-citation></ref><ref id="B114-cancers-16-01191"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liberto</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>I.-M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.-L.</given-names></name><name name-style="western"><surname>Pisanic</surname><given-names>T.R.</given-names></name></person-group><article-title>Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>2885</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14122885</pub-id><pub-id pub-id-type="pmid">35740550</pub-id><pub-id pub-id-type="pmcid">PMC9221480</pub-id></element-citation></ref><ref id="B115-cancers-16-01191"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waleleng</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Adiwinata</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wenas</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Haroen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rotty</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gosal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rotty</surname><given-names>L.</given-names></name><name name-style="western"><surname>Winarta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waleleng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simadibrata</surname><given-names>M.</given-names></name></person-group><article-title>Screening of Pancreatic Cancer: Target Population, Optimal Timing and How?</article-title><source>Ann. Med. Surg.</source><year>2022</year><volume>84</volume><fpage>104814</fpage><pub-id pub-id-type="doi">10.1016/j.amsu.2022.104814</pub-id><pub-id pub-id-type="pmid">36582884</pub-id><pub-id pub-id-type="pmcid">PMC9793126</pub-id></element-citation></ref><ref id="B116-cancers-16-01191"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rovito</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Manjelievskaia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Nangia</surname><given-names>A.</given-names></name></person-group><article-title>From &#8216;D&#8217; to &#8216;I&#8217;: A Critique of the Current United States Preventive Services Task Force Recommendation for Testicular Cancer Screening</article-title><source>Prev. Med. Rep.</source><year>2016</year><volume>3</volume><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2016.04.006</pub-id><pub-id pub-id-type="pmid">27419037</pub-id><pub-id pub-id-type="pmcid">PMC4929233</pub-id></element-citation></ref><ref id="B117-cancers-16-01191"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Souza-Schorey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>J.W.</given-names></name></person-group><article-title>Tumor-Derived Microvesicles: Shedding Light on Novel Microenvironment Modulators and Prospective Cancer Biomarkers</article-title><source>Genes. Dev.</source><year>2012</year><volume>26</volume><fpage>1287</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1101/gad.192351.112</pub-id><pub-id pub-id-type="pmid">22713869</pub-id><pub-id pub-id-type="pmcid">PMC3387656</pub-id></element-citation></ref><ref id="B118-cancers-16-01191"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Alpaugh</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Charpentier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bergan</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Catalona</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chumsri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.-M.</given-names></name><etal/></person-group><article-title>Circulating Giant Macrophages as a Potential Biomarker of Solid Tumors</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>3514</fpage><lpage>3519</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320198111</pub-id><pub-id pub-id-type="pmid">24550495</pub-id><pub-id pub-id-type="pmcid">PMC3948254</pub-id></element-citation></ref><ref id="B119-cancers-16-01191"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macdonald</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Parsy-Kowalska</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>C.J.</given-names></name></person-group><article-title>Autoantibodies: Opportunities for Early Cancer Detection</article-title><source>Trends Cancer</source><year>2017</year><volume>3</volume><fpage>198</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.02.003</pub-id><pub-id pub-id-type="pmid">28718432</pub-id></element-citation></ref><ref id="B120-cancers-16-01191"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasseur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kiavue</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bidard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pierga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cabel</surname><given-names>L.</given-names></name></person-group><article-title>Clinical Utility of Circulating Tumor Cells: An Update</article-title><source>Mol. Oncol.</source><year>2021</year><volume>15</volume><fpage>1647</fpage><lpage>1666</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12869</pub-id><pub-id pub-id-type="pmid">33289351</pub-id><pub-id pub-id-type="pmcid">PMC8169442</pub-id></element-citation></ref><ref id="B121-cancers-16-01191"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flores</surname><given-names>B.C.T.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Henrique</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jer&#243;nimo</surname><given-names>C.</given-names></name></person-group><article-title>Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>4209</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13164209</pub-id><pub-id pub-id-type="pmid">34439363</pub-id><pub-id pub-id-type="pmcid">PMC8391503</pub-id></element-citation></ref><ref id="B122-cancers-16-01191"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crook</surname><given-names>T.</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mokbel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Page</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ranade</surname><given-names>A.</given-names></name><name name-style="western"><surname>Limaye</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>3341</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14143341</pub-id><pub-id pub-id-type="pmid">35884402</pub-id><pub-id pub-id-type="pmcid">PMC9316476</pub-id></element-citation></ref><ref id="B123-cancers-16-01191"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>V.</given-names></name><name name-style="western"><surname>Long-Mira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Selva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vignaud</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Padovani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mouroux</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marquette</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>P.</given-names></name></person-group><article-title>&#8220;Sentinel&#8221; Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e111597</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0111597</pub-id><pub-id pub-id-type="pmid">25360587</pub-id><pub-id pub-id-type="pmcid">PMC4216113</pub-id></element-citation></ref><ref id="B124-cancers-16-01191"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>P.</given-names></name></person-group><article-title>Distribution and Clinical Analysis of EpCAM+/Vimentin+ Circulating Tumor Cells in High-Risk Population and Cancer Patients</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><fpage>642971</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.642971</pub-id><pub-id pub-id-type="pmid">34168982</pub-id><pub-id pub-id-type="pmcid">PMC8217642</pub-id></element-citation></ref><ref id="B125-cancers-16-01191"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hillig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Horn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nygaard</surname><given-names>A.-B.</given-names></name><name name-style="western"><surname>Haugaard</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Nejlund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brandslund</surname><given-names>I.</given-names></name><name name-style="western"><surname>S&#246;l&#233;tormos</surname><given-names>G.</given-names></name></person-group><article-title>In Vitro Detection of Circulating Tumor Cells Compared by the CytoTrack and CellSearch Methods</article-title><source>Tumour Biol.</source><year>2015</year><volume>36</volume><fpage>4597</fpage><lpage>4601</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3105-z</pub-id><pub-id pub-id-type="pmid">25608842</pub-id><pub-id pub-id-type="pmcid">PMC4529454</pub-id></element-citation></ref><ref id="B126-cancers-16-01191"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akolkar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>D.</given-names></name><name name-style="western"><surname>Crook</surname><given-names>T.</given-names></name><name name-style="western"><surname>Limaye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Page</surname><given-names>R.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ranade</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fulmali</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Circulating Ensembles of Tumor-Associated Cells: A Redoubtable New Systemic Hallmark of Cancer</article-title><source>Int. J. Cancer</source><year>2020</year><volume>146</volume><fpage>3485</fpage><lpage>3494</lpage><pub-id pub-id-type="doi">10.1002/ijc.32815</pub-id><pub-id pub-id-type="pmid">31785151</pub-id><pub-id pub-id-type="pmcid">PMC7217040</pub-id></element-citation></ref><ref id="B127-cancers-16-01191"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crook</surname><given-names>T.</given-names></name><name name-style="western"><surname>Plowman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ranade</surname><given-names>A.</given-names></name><name name-style="western"><surname>Limaye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Page</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fulmali</surname><given-names>P.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Evaluation of Circulating Tumor Cell Clusters for Pan-cancer Noninvasive Diagnostic Triaging</article-title><source>Cancer Cytopathol.</source><year>2021</year><volume>129</volume><fpage>226</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1002/cncy.22366</pub-id><pub-id pub-id-type="pmid">32996712</pub-id><pub-id pub-id-type="pmcid">PMC7984349</pub-id></element-citation></ref><ref id="B128-cancers-16-01191"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inaba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shimozono</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yabuki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Enomoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirotsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>di Luccio</surname><given-names>E.</given-names></name></person-group><article-title>Accuracy Evaluation of the C. Elegans Cancer Test (N-NOSE) Using a New Combined Method</article-title><source>Cancer Treat. Res. Commun.</source><year>2021</year><volume>27</volume><fpage>100370</fpage><pub-id pub-id-type="doi">10.1016/j.ctarc.2021.100370</pub-id><pub-id pub-id-type="pmid">33901923</pub-id></element-citation></ref><ref id="B129-cancers-16-01191"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tzanikou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lianidou</surname><given-names>E.</given-names></name></person-group><article-title>The Potential of Liquid Biopsy in the Management of Cancer Patients</article-title><source>Semin. Cancer Biol.</source><year>2022</year><volume>84</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2022.03.013</pub-id><pub-id pub-id-type="pmid">35331850</pub-id></element-citation></ref><ref id="B130-cancers-16-01191"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poulet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Massias</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taly</surname><given-names>V.</given-names></name></person-group><article-title>Liquid Biopsy: General Concepts</article-title><source>Acta Cytol.</source><year>2019</year><volume>63</volume><fpage>449</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1159/000499337</pub-id><pub-id pub-id-type="pmid">31091522</pub-id></element-citation></ref><ref id="B131-cancers-16-01191"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ignatiadis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sledge</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Jeffrey</surname><given-names>S.S.</given-names></name></person-group><article-title>Liquid Biopsy Enters the Clinic&#8212;Implementation Issues and Future Challenges</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2021</year><volume>18</volume><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00457-x</pub-id><pub-id pub-id-type="pmid">33473219</pub-id></element-citation></ref><ref id="B132-cancers-16-01191"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehrabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Millingen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aikhionbare</surname><given-names>F.O.</given-names></name></person-group><article-title>Reactive Oxygen Species and Serous Epithelial Ovarian Adenocarcinoma</article-title><source>Cancer Res. J.</source><year>2016</year><volume>4</volume><fpage>106</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.11648/j.crj.20160406.13</pub-id><pub-id pub-id-type="pmcid">PMC5427055</pub-id><pub-id pub-id-type="pmid">28503633</pub-id></element-citation></ref><ref id="B133-cancers-16-01191"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pons-Belda</surname><given-names>O.D.</given-names></name><name name-style="western"><surname>Fernandez-Uriarte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diamandis</surname><given-names>E.P.</given-names></name></person-group><article-title>Multi Cancer Early Detection by Using Circulating Tumor DNA-The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on &#8220;Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171&#8221;</article-title><source>Diagnostics</source><year>2022</year><volume>12</volume><elocation-id>1244</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics12051244</pub-id><pub-id pub-id-type="pmid">35626399</pub-id><pub-id pub-id-type="pmcid">PMC9141547</pub-id></element-citation></ref><ref id="B134-cancers-16-01191"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Oxnard</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seiden</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Oxnard</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Sensitive and Specific Multi-Cancer Detection and Localization Using Methylation Signatures in Cell-Free DNA</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>745</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.02.011</pub-id><pub-id pub-id-type="pmid">33506766</pub-id><pub-id pub-id-type="pmcid">PMC8274402</pub-id></element-citation></ref><ref id="B135-cancers-16-01191"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tummala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lapham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>G.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hunkapiller</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set</article-title><source>Ann. Oncol.</source><year>2021</year><volume>32</volume><fpage>1167</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.05.806</pub-id><pub-id pub-id-type="pmid">34176681</pub-id></element-citation></ref><ref id="B136-cancers-16-01191"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoshino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Bojmar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gyan</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cioffi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zambirinis</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>G.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>H.</given-names></name><name name-style="western"><surname>Heissel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1044</fpage><lpage>1061.e18</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.009</pub-id><pub-id pub-id-type="pmid">32795414</pub-id><pub-id pub-id-type="pmcid">PMC7522766</pub-id></element-citation></ref><ref id="B137-cancers-16-01191"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doyle</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.Z.</given-names></name></person-group><article-title>Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>727</elocation-id><pub-id pub-id-type="doi">10.3390/cells8070727</pub-id><pub-id pub-id-type="pmid">31311206</pub-id><pub-id pub-id-type="pmcid">PMC6678302</pub-id></element-citation></ref><ref id="B138-cancers-16-01191"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urabe</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kosaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Egawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ochiya</surname><given-names>T.</given-names></name></person-group><article-title>Extracellular Vesicles as Biomarkers and Therapeutic Targets for Cancer</article-title><source>Am. J. Physiol.-Cell Physiol.</source><year>2020</year><volume>318</volume><fpage>C29</fpage><lpage>C39</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00280.2019</pub-id><pub-id pub-id-type="pmid">31693397</pub-id></element-citation></ref><ref id="B139-cancers-16-01191"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chakrabortty</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Enderle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Noerholm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Breakefield</surname><given-names>X.O.</given-names></name><name name-style="western"><surname>Skog</surname><given-names>J.K.</given-names></name></person-group><article-title>Exosome-Based Liquid Biopsies in Cancer: Opportunities and Challenges</article-title><source>Ann. Oncol.</source><year>2021</year><volume>32</volume><fpage>466</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.01.074</pub-id><pub-id pub-id-type="pmid">33548389</pub-id><pub-id pub-id-type="pmcid">PMC8268076</pub-id></element-citation></ref><ref id="B140-cancers-16-01191"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldvaser</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gutkin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beery</surname><given-names>E.</given-names></name><name name-style="western"><surname>Edel</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nordenberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wolach</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rabizadeh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Uziel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lahav</surname><given-names>M.</given-names></name></person-group><article-title>Characterisation of Blood-Derived Exosomal hTERT mRNA Secretion in Cancer Patients: A Potential Pan-Cancer Marker</article-title><source>Br. J. Cancer</source><year>2017</year><volume>117</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.166</pub-id><pub-id pub-id-type="pmid">28641311</pub-id><pub-id pub-id-type="pmcid">PMC5537487</pub-id></element-citation></ref><ref id="B141-cancers-16-01191"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinestrosa</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schork</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kamat</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lowy</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Eskander</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Perrera</surname><given-names>O.</given-names></name><name name-style="western"><surname>Searson</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle Protein-Based Blood Test</article-title><source>Commun. Med.</source><year>2022</year><volume>2</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1038/s43856-022-00088-6</pub-id><pub-id pub-id-type="pmid">35603292</pub-id><pub-id pub-id-type="pmcid">PMC9053211</pub-id></element-citation></ref><ref id="B142-cancers-16-01191"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Localized Fluorescent Imaging of Multiple Proteins on Individual Extracellular Vesicles Using Rolling Circle Amplification for Cancer Diagnosis</article-title><source>J. Extracell. Vesicles</source><year>2020</year><volume>10</volume><fpage>12025</fpage><pub-id pub-id-type="doi">10.1002/jev2.12025</pub-id><pub-id pub-id-type="pmcid">PMC7710127</pub-id><pub-id pub-id-type="pmid">33304477</pub-id></element-citation></ref><ref id="B143-cancers-16-01191"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Low-Cost Thermophoretic Profiling of Extracellular-Vesicle Surface Proteins for the Early Detection and Classification of Cancers</article-title><source>Nat. Biomed. Eng.</source><year>2019</year><volume>3</volume><fpage>183</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1038/s41551-018-0343-6</pub-id><pub-id pub-id-type="pmid">30948809</pub-id></element-citation></ref><ref id="B144-cancers-16-01191"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yanagida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Konakade</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>D.</given-names></name><name name-style="western"><surname>Naganawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaji</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Unveiling Massive Numbers of Cancer-Related Urinary-microRNA Candidates via Nanowires</article-title><source>Sci. Adv.</source><year>2017</year><volume>3</volume><fpage>e1701133</fpage><pub-id pub-id-type="doi">10.1126/sciadv.1701133</pub-id><pub-id pub-id-type="pmid">29291244</pub-id><pub-id pub-id-type="pmcid">PMC5744465</pub-id></element-citation></ref><ref id="B145-cancers-16-01191"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczor-Urbanowicz</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Mart&#237;n Carreras-Presas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaczor</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garcia-Godoy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D.T.W.</given-names></name></person-group><article-title>Emerging Technologies for Salivaomics in Cancer Detection</article-title><source>J. Cell Mol. Med.</source><year>2017</year><volume>21</volume><fpage>640</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13007</pub-id><pub-id pub-id-type="pmid">27862926</pub-id><pub-id pub-id-type="pmcid">PMC5345659</pub-id></element-citation></ref><ref id="B146-cancers-16-01191"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daily</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ravishankar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klimberg</surname><given-names>V.S.</given-names></name></person-group><article-title>Using Tears as a Non-Invasive Source for Early Detection of Breast Cancer</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0267676</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0267676</pub-id><pub-id pub-id-type="pmid">35471994</pub-id><pub-id pub-id-type="pmcid">PMC9041847</pub-id></element-citation></ref><ref id="B147-cancers-16-01191"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krilaviciute</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heiss</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Leja</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kupcinskas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haick</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>H.</given-names></name></person-group><article-title>Detection of Cancer through Exhaled Breath: A Systematic Review</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>38643</fpage><lpage>38657</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5938</pub-id><pub-id pub-id-type="pmid">26440312</pub-id><pub-id pub-id-type="pmcid">PMC4770726</pub-id></element-citation></ref><ref id="B148-cancers-16-01191"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lidgard</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Domanico</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bruinsma</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Light</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gagrat</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Oldham&#8211;Haltom</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Fourrier</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Allawi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yab</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>W.R.</given-names></name><etal/></person-group><article-title>Clinical Performance of an Automated Stool DNA Assay for Detection of Colorectal Neoplasia</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2013</year><volume>11</volume><fpage>1313</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2013.04.023</pub-id><pub-id pub-id-type="pmid">23639600</pub-id></element-citation></ref><ref id="B149-cancers-16-01191"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redwood</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Asay</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Tiesinga</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Devens</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Alberts</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Mahoney</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People</article-title><source>Mayo Clin. Proc.</source><year>2016</year><volume>91</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2015.10.008</pub-id><pub-id pub-id-type="pmid">26520415</pub-id></element-citation></ref><ref id="B150-cancers-16-01191"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imperiale</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Ransohoff</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Itzkowitz</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Lavin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lidgard</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Ahlquist</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>B.M.</given-names></name></person-group><article-title>Multitarget Stool DNA Testing for Colorectal-Cancer Screening</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>1287</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1311194</pub-id><pub-id pub-id-type="pmid">24645800</pub-id></element-citation></ref><ref id="B151-cancers-16-01191"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnell</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Wurtzler</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>La Rocca</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>T.</given-names></name><name name-style="western"><surname>Petrone</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>D.A.</given-names></name></person-group><article-title>Multitarget Stool RNA Test for Colorectal Cancer Screening</article-title><source>JAMA</source><year>2023</year><volume>330</volume><fpage>1760</fpage><lpage>1768</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.22231</pub-id><pub-id pub-id-type="pmid">37870871</pub-id><pub-id pub-id-type="pmcid">PMC10594178</pub-id></element-citation></ref><ref id="B152-cancers-16-01191"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Currais</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Claro</surname><given-names>I.</given-names></name></person-group><article-title>Colorectal Cancer Carcinogenesis: From Bench to Bedside</article-title><source>World J. Gastrointest. Oncol.</source><year>2022</year><volume>14</volume><fpage>654</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.4251/wjgo.v14.i3.654</pub-id><pub-id pub-id-type="pmid">35321283</pub-id><pub-id pub-id-type="pmcid">PMC8919024</pub-id></element-citation></ref><ref id="B153-cancers-16-01191"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakkum-Gamez</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Wentzensen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hawthorne</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kroneman</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Famuyide</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Halling</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>Detection of Endometrial Cancer via Molecular Analysis of DNA Collected with Vaginal Tampons</article-title><source>Gynecol. Oncol.</source><year>2015</year><volume>137</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.01.552</pub-id><pub-id pub-id-type="pmid">25677060</pub-id><pub-id pub-id-type="pmcid">PMC4380654</pub-id></element-citation></ref><ref id="B154-cancers-16-01191"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Douville</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>T.-T.</given-names></name><name name-style="western"><surname>Kinde</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sundfelt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kj&#230;r</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Hruban</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>I.-M.</given-names></name><etal/></person-group><article-title>Evaluation of Liquid from the Papanicolaou Test and Other Liquid Biopsies for the Detection of Endometrial and Ovarian Cancers</article-title><source>Sci. Transl. Med.</source><year>2018</year><volume>10</volume><fpage>eaap8793</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aap8793</pub-id><pub-id pub-id-type="pmid">29563323</pub-id><pub-id pub-id-type="pmcid">PMC6320220</pub-id></element-citation></ref><ref id="B155-cancers-16-01191"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryce</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Seiden</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>D.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Coignet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kurtzman</surname><given-names>K.N.</given-names></name><etal/></person-group><article-title>Performance of a Cell-Free DNA-Based Multi-Cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancers</article-title><source>JCO Precis. Oncol.</source><year>2023</year><volume>7</volume><fpage>e2200679</fpage><pub-id pub-id-type="doi">10.1200/PO.22.00679</pub-id><pub-id pub-id-type="pmid">37467458</pub-id><pub-id pub-id-type="pmcid">PMC10581635</pub-id></element-citation></ref><ref id="B156-cancers-16-01191"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhamani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Horst</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bojang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quaife</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Tisi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>H.</given-names></name><name name-style="western"><surname>Verghese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Creamer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prendecki</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The SUMMIT Study: Utilising a Written &#8216;Next Steps&#8217; Information Booklet to Prepare Participants for Potential Lung Cancer Screening Results and Follow-Up</article-title><source>Lung Cancer</source><year>2023</year><volume>176</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2022.12.006</pub-id><pub-id pub-id-type="pmid">36621036</pub-id><pub-id pub-id-type="pmcid">PMC7615157</pub-id></element-citation></ref><ref id="B157-cancers-16-01191"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadauld</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Beer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Hudnut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Oxnard</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Lipson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>3501</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13143501</pub-id><pub-id pub-id-type="pmid">34298717</pub-id><pub-id pub-id-type="pmcid">PMC8304888</pub-id></element-citation></ref><ref id="B158-cancers-16-01191"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schrag</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Nadauld</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dilaveri</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marinac</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Lopatin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>E.T.</given-names></name><etal/></person-group><article-title>Blood-Based Tests for Multicancer Early Detection (PATHFINDER): A Prospective Cohort Study</article-title><source>Lancet</source><year>2023</year><volume>402</volume><fpage>1251</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01700-2</pub-id><pub-id pub-id-type="pmid">37805216</pub-id><pub-id pub-id-type="pmcid">PMC11027492</pub-id></element-citation></ref><ref id="B159-cancers-16-01191"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westgate</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salles</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lopatin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurtzman</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Kappes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Venn</surname><given-names>O.</given-names></name><name name-style="western"><surname>Parekh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Venstrom</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Younes</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms</article-title><source>Blood</source><year>2023</year><volume>142</volume><fpage>3646</fpage><pub-id pub-id-type="doi">10.1182/blood-2023-186481</pub-id></element-citation></ref><ref id="B160-cancers-16-01191"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neal</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sasieni</surname><given-names>P.</given-names></name></person-group><article-title>Cell-Free DNA&#8211;Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>4818</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14194818</pub-id><pub-id pub-id-type="pmid">36230741</pub-id><pub-id pub-id-type="pmcid">PMC9564213</pub-id></element-citation></ref><ref id="B161-cancers-16-01191"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasieni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smittenaar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Broggio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></name></person-group><article-title>Modelled Mortality Benefits of Multi-Cancer Early Detection Screening in England</article-title><source>Br. J. Cancer</source><year>2023</year><volume>129</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/s41416-023-02243-9</pub-id><pub-id pub-id-type="pmid">37185463</pub-id><pub-id pub-id-type="pmcid">PMC10307803</pub-id></element-citation></ref><ref id="B162-cancers-16-01191"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brentnall</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beare</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ching</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sleeth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sasieni</surname><given-names>P.</given-names></name></person-group><article-title>Dynamic Data-Enabled Stratified Sampling for Trial Invitations with Application in NHS-Galleri</article-title><source>Clin. Trials</source><year>2023</year><volume>20</volume><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1177/17407745231167369</pub-id><pub-id pub-id-type="pmid">37095697</pub-id><pub-id pub-id-type="pmcid">PMC10338700</pub-id></element-citation></ref><ref id="B163-cancers-16-01191"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bratulic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Limeta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dabestani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Birgisson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Enblad</surname><given-names>G.</given-names></name><name name-style="western"><surname>St&#229;lberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hesselager</surname><given-names>G.</given-names></name><name name-style="western"><surname>H&#228;ggman</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#246;glund</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simonson</surname><given-names>O.E.</given-names></name><etal/></person-group><article-title>Noninvasive Detection of Any-Stage Cancer Using Free Glycosaminoglycans</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2115328119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2115328119</pub-id><pub-id pub-id-type="pmid">36469776</pub-id><pub-id pub-id-type="pmcid">PMC9897435</pub-id></element-citation></ref><ref id="B164-cancers-16-01191"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><etal/></person-group><article-title>909P A Multi-Cancer Early Detection Model Based on Liquid Biopsy of Multi-Omics Biomarkers: A Proof of Concept Study (PROMISE Study)</article-title><source>Ann. Oncol.</source><year>2022</year><volume>33</volume><fpage>S963</fpage><lpage>S964</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.07.1035</pub-id></element-citation></ref><ref id="B165-cancers-16-01191"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.Q.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.L.</given-names></name><etal/></person-group><article-title>Unintrusive Multi-Cancer Detection by Circulating Cell-Free DNA Methylation Sequencing (THUNDER): Development and Independent Validation Studies</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.02.010</pub-id><pub-id pub-id-type="pmid">36849097</pub-id></element-citation></ref><ref id="B166-cancers-16-01191"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Su</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>LBA3 Early Detection and Localization of Multiple Cancers Using a Blood-Based Methylation Assay (ELSA-Seq)</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>S1358</fpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.10.292</pub-id></element-citation></ref><ref id="B167-cancers-16-01191"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ris</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hellan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Douissard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nieva</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Triponez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geller</surname><given-names>D.</given-names></name><name name-style="western"><surname>Buchs</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Buehler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moenig</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGENTM): Early Clinical Results</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>4104</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13164104</pub-id><pub-id pub-id-type="pmid">34439258</pub-id><pub-id pub-id-type="pmcid">PMC8392437</pub-id></element-citation></ref><ref id="B168-cancers-16-01191"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Billan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>U.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dvrokind</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marom</surname><given-names>O.</given-names></name><name name-style="western"><surname>Abdah-Bortnyak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuten</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haick</surname><given-names>H.</given-names></name></person-group><article-title>Diagnosis of Head-and-Neck Cancer from Exhaled Breath</article-title><source>Br. J. Cancer</source><year>2011</year><volume>104</volume><fpage>1649</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.128</pub-id><pub-id pub-id-type="pmid">21505455</pub-id><pub-id pub-id-type="pmcid">PMC3101906</pub-id></element-citation></ref><ref id="B169-cancers-16-01191"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hakim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broza</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Billan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abdah-Bortnyak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuten</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>U.</given-names></name><name name-style="western"><surname>Haick</surname><given-names>H.</given-names></name></person-group><article-title>Detection of Lung, Breast, Colorectal, and Prostate Cancers from Exhaled Breath Using a Single Array of Nanosensors</article-title><source>Br. J. Cancer</source><year>2010</year><volume>103</volume><fpage>542</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605810</pub-id><pub-id pub-id-type="pmid">20648015</pub-id><pub-id pub-id-type="pmcid">PMC2939793</pub-id></element-citation></ref><ref id="B170-cancers-16-01191"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Min</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fleshner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Knox</surname><given-names>J.</given-names></name><name name-style="western"><surname>May</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ailles</surname><given-names>L.</given-names></name><name name-style="western"><surname>Newton</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singhania</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Abstract 1030: Development of a Genome-Wide Methylome Enrichment Platform for Multi-Cancer Early Detection (MCED)</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><fpage>1030</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2023-1030</pub-id></element-citation></ref><ref id="B171-cancers-16-01191"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>H.T.-H.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>L.S.</given-names></name></person-group><article-title>Clinical Validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants</article-title><source>JCO Glob. Oncol.</source><year>2023</year><volume>9</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1200/GO.2023.9.Supplement_1.135</pub-id><pub-id pub-id-type="pmid">36719061</pub-id></element-citation></ref><ref id="B172-cancers-16-01191"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>L.H.D.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.H.H.</given-names></name></person-group><article-title>LBA2 Analytical and Clinical Validation of a ctDNA-Based Assay for Multi-Cancer Detection</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>S1467</fpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.10.131</pub-id><pub-id pub-id-type="pmid">36719061</pub-id></element-citation></ref><ref id="B173-cancers-16-01191"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Abstract 4194: The FuSion Project of Pan-Cancer Early Screening in Chinese&#8211; An Integrative Study by Fudan University and Singlera</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><fpage>4194</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2023-4194</pub-id></element-citation></ref><ref id="B174-cancers-16-01191"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chanteloup</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cordonnier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Isambert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bertaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marcion</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gobbo</surname><given-names>J.</given-names></name></person-group><article-title>Membrane-Bound Exosomal HSP70 as a Biomarker for Detection and Monitoring of Malignant Solid Tumours: A Pilot Study</article-title><source>Pilot. Feasibility Stud.</source><year>2020</year><volume>6</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s40814-020-00577-2</pub-id><pub-id pub-id-type="pmid">32161659</pub-id><pub-id pub-id-type="pmcid">PMC7053097</pub-id></element-citation></ref><ref id="B175-cancers-16-01191"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Letter to the Editor: An Ultra-Sensitive Assay Using Cell-Free DNA Fragmentomics for Multi-Cancer Early Detection</article-title><source>Mol. Cancer</source><year>2022</year><volume>21</volume><fpage>129</fpage><pub-id pub-id-type="doi">10.1186/s12943-022-01594-w</pub-id><pub-id pub-id-type="pmid">35690859</pub-id><pub-id pub-id-type="pmcid">PMC9188251</pub-id></element-citation></ref><ref id="B176-cancers-16-01191"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzone</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.-K.</given-names></name><name name-style="western"><surname>Tsay</surname><given-names>J.-C.J.</given-names></name><name name-style="western"><surname>Pass</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Vachani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jakubowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Abstract 5766: Prospective Evaluation of Cell-Free DNA Fragmentomes for Lung Cancer Detection</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><fpage>5766</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2023-5766</pub-id></element-citation></ref><ref id="B177-cancers-16-01191"><label>177.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Pommergaard</surname><given-names>H.-C.</given-names></name></person-group><article-title>Early Detection of de Novo Cancer in Liver Transplant Recipients&#8212;A ScandiaTransplant Collaboration</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05492617" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05492617</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-03">(accessed on 3 March 2024)</date-in-citation></element-citation></ref><ref id="B178-cancers-16-01191"><label>178.</label><element-citation publication-type="gov"><article-title>Harbinger Health Cancer ORigin Epigenetics-Harbinger Health&#8212;Collection of Blood and Tissue Samples From Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05435066" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05435066</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-03">(accessed on 3 March 2024)</date-in-citation></element-citation></ref><ref id="B179-cancers-16-01191"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Vento-Gaudens</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eagle</surname><given-names>C.</given-names></name></person-group><article-title>Screening for High Frequency Malignant Disease (SHIELD)</article-title><source>JCO</source><year>2022</year><volume>40</volume><fpage>TPS1602</fpage><pub-id pub-id-type="doi">10.1200/JCO.2022.40.16_suppl.TPS1602</pub-id></element-citation></ref><ref id="B180-cancers-16-01191"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raymond</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vento-Gaudens</surname><given-names>E.</given-names></name><name name-style="western"><surname>Eagle</surname><given-names>C.</given-names></name></person-group><article-title>PP01.20 Trial in Progress: Screening for High Frequency Malignant Disease (SHIELD)</article-title><source>J. Thorac. Oncol.</source><year>2023</year><volume>18</volume><fpage>e19</fpage><pub-id pub-id-type="doi">10.1016/j.jtho.2022.09.046</pub-id></element-citation></ref><ref id="B181-cancers-16-01191"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raymond</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>K.</given-names></name></person-group><article-title>Evaluation of the ctDNA LUNAR-2 Test in an Average Patient Screening Episode (ECLIPSE)</article-title><source>JCO</source><year>2021</year><volume>39</volume><fpage>TPS142</fpage><pub-id pub-id-type="doi">10.1200/JCO.2021.39.3_suppl.TPS142</pub-id></element-citation></ref><ref id="B182-cancers-16-01191"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackshaw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>A.-R.</given-names></name></person-group><article-title>New Genomic Technologies for Multi-Cancer Early Detection: Rethinking the Scope of Cancer Screening</article-title><source>Cancer Cell</source><year>2022</year><volume>40</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2022.01.012</pub-id><pub-id pub-id-type="pmid">35120599</pub-id></element-citation></ref><ref id="B183-cancers-16-01191"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Burgener</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bratman</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>De Carvalho</surname><given-names>D.D.</given-names></name></person-group><article-title>Preparation of cfMeDIP-Seq Libraries for Methylome Profiling of Plasma Cell-Free DNA</article-title><source>Nat. Protoc.</source><year>2019</year><volume>14</volume><fpage>2749</fpage><lpage>2780</lpage><pub-id pub-id-type="doi">10.1038/s41596-019-0202-2</pub-id><pub-id pub-id-type="pmid">31471598</pub-id></element-citation></ref><ref id="B184-cancers-16-01191"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Twombly</surname><given-names>R.</given-names></name></person-group><article-title>Full-Body CT Screening: Preventing or Producing Cancer?</article-title><source>JNCI J. Natl. Cancer Inst.</source><year>2004</year><volume>96</volume><fpage>1650</fpage><lpage>1651</lpage><pub-id pub-id-type="doi">10.1093/jnci/96.22.1650</pub-id><pub-id pub-id-type="pmid">15547173</pub-id></element-citation></ref><ref id="B185-cancers-16-01191"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welch</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Schroeck</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Black</surname><given-names>W.C.</given-names></name></person-group><article-title>Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy</article-title><source>JAMA Intern. Med.</source><year>2018</year><volume>178</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2017.7508</pub-id><pub-id pub-id-type="pmid">29279887</pub-id><pub-id pub-id-type="pmcid">PMC5838611</pub-id></element-citation></ref><ref id="B186-cancers-16-01191"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tipirneni</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Haskins</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Udayakumar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jani</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Morlandt</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Bogyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Fluorescence Imaging for Cancer Screening and Surveillance</article-title><source>Mol. Imaging Biol.</source><year>2017</year><volume>19</volume><fpage>645</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1007/s11307-017-1050-5</pub-id><pub-id pub-id-type="pmid">28155079</pub-id></element-citation></ref><ref id="B187-cancers-16-01191"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Khandhar</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Goodwill</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Conolly</surname><given-names>S.M.</given-names></name></person-group><article-title>Magnetic Particle Imaging: A Novel in Vivo Imaging Platform for Cancer Detection</article-title><source>Nano Lett.</source><year>2017</year><volume>17</volume><fpage>1648</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.6b04865</pub-id><pub-id pub-id-type="pmid">28206771</pub-id><pub-id pub-id-type="pmcid">PMC5724561</pub-id></element-citation></ref><ref id="B188-cancers-16-01191"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gambhir</surname><given-names>S.S.</given-names></name></person-group><article-title>Tumor Molecular Imaging with Nanoparticles</article-title><source>Engineering</source><year>2016</year><volume>2</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/J.ENG.2016.01.027</pub-id></element-citation></ref><ref id="B189-cancers-16-01191"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shumilov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Flach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pabst</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angelillo-Scherrer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tr&#252;mper</surname><given-names>L.</given-names></name><name name-style="western"><surname>Joncourt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kohlmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bacher</surname><given-names>U.</given-names></name></person-group><article-title>Genetic Alterations Crossing the Borders of Distinct Hematopoetic Lineages and Solid Tumors: Diagnostic Challenges in the Era of High-Throughput Sequencing in Hemato-Oncology</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2018</year><volume>126</volume><fpage>64</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2018.03.020</pub-id><pub-id pub-id-type="pmid">29759569</pub-id></element-citation></ref><ref id="B190-cancers-16-01191"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tivey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Church</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dive</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>N.</given-names></name></person-group><article-title>Circulating Tumour DNA&#8212;Looking beyond the Blood</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2022</year><volume>19</volume><fpage>600</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00660-y</pub-id><pub-id pub-id-type="pmid">35915225</pub-id><pub-id pub-id-type="pmcid">PMC9341152</pub-id></element-citation></ref><ref id="B191-cancers-16-01191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Boshier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Myridakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belluomo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>G.B.</given-names></name></person-group><article-title>Urinary Volatile Organic Compound Analysis for the Diagnosis of Cancer: A Systematic Literature Review and Quality Assessment</article-title><source>Metabolites</source><year>2020</year><volume>11</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3390/metabo11010017</pub-id><pub-id pub-id-type="pmid">33383923</pub-id><pub-id pub-id-type="pmcid">PMC7824454</pub-id></element-citation></ref><ref id="B192-cancers-16-01191"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saalberg</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>M.</given-names></name></person-group><article-title>VOC Breath Biomarkers in Lung Cancer</article-title><source>Clin. Chim. Acta</source><year>2016</year><volume>459</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2016.05.013</pub-id><pub-id pub-id-type="pmid">27221203</pub-id></element-citation></ref><ref id="B193-cancers-16-01191"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Staib</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schmidtmann</surname><given-names>I.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schimanski</surname><given-names>C.C.</given-names></name></person-group><article-title>Sniffer Dogs Can Identify Lung Cancer Patients from Breath and Urine Samples</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><elocation-id>917</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-021-08651-5</pub-id><pub-id pub-id-type="pmid">34388977</pub-id><pub-id pub-id-type="pmcid">PMC8362224</pub-id></element-citation></ref><ref id="B194-cancers-16-01191"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallafr&#233;-Muro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Llambrich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cumeras</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brezmes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gum&#224;</surname><given-names>J.</given-names></name></person-group><article-title>Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>2534</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13112534</pub-id><pub-id pub-id-type="pmid">34064065</pub-id><pub-id pub-id-type="pmcid">PMC8196698</pub-id></element-citation></ref><ref id="B195-cancers-16-01191"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lima</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carvalho-Maia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jer&#243;nimo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Henrique</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>M.d.L.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guedes de Pinho</surname><given-names>P.</given-names></name></person-group><article-title>A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>2017</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12082017</pub-id><pub-id pub-id-type="pmid">32717987</pub-id><pub-id pub-id-type="pmcid">PMC7464354</pub-id></element-citation></ref><ref id="B196-cancers-16-01191"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pires-Lu&#237;s</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Henrique</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jer&#243;nimo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>M.</given-names></name></person-group><article-title>de L.; Gil, A.M.; Carvalho, M.; Guedes de Pinho, P. GC-MS Metabolomics-based Approach for the Identification of a Potential VOC-biomarker Panel in the Urine of Renal Cell Carcinoma Patients</article-title><source>J. Cell Mol. Med.</source><year>2017</year><volume>21</volume><fpage>2092</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13132</pub-id><pub-id pub-id-type="pmid">28378454</pub-id><pub-id pub-id-type="pmcid">PMC5571542</pub-id></element-citation></ref><ref id="B197-cancers-16-01191"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gir&#243; Benet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gum&#224; Padr&#243;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pardo Martnez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kurdahi</surname><given-names>F.</given-names></name></person-group><article-title>Breast Cancer Detection by Analyzing the Volatile Organic Compound (VOC) Signature in Human Urine</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>14873</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-17795-8</pub-id><pub-id pub-id-type="pmid">36050339</pub-id><pub-id pub-id-type="pmcid">PMC9435419</pub-id></element-citation></ref><ref id="B198-cancers-16-01191"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.Z.S.C.</given-names></name></person-group><article-title>Elegans: A Sensible Model for Sensory Biology</article-title><source>J. Neurogenet.</source><year>2020</year><volume>34</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1080/01677063.2020.1823386</pub-id><pub-id pub-id-type="pmid">33191820</pub-id><pub-id pub-id-type="pmcid">PMC7856205</pub-id></element-citation></ref><ref id="B199-cancers-16-01191"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girard</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F.</given-names></name><name name-style="western"><surname>Antoshechkin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Han</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sternberg</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Chalfie</surname><given-names>M.</given-names></name></person-group><article-title>WormBook: The Online Review of Caenorhabditis Elegans Biology</article-title><source>Nucleic Acids Res.</source><year>2007</year><volume>35</volume><fpage>D472</fpage><lpage>D475</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl894</pub-id><pub-id pub-id-type="pmid">17099225</pub-id><pub-id pub-id-type="pmcid">PMC1669767</pub-id></element-citation></ref><ref id="B200-cancers-16-01191"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bargmann</surname><given-names>C.I.</given-names></name></person-group><article-title>Comparative Chemosensation from Receptors to Ecology</article-title><source>Nature</source><year>2006</year><volume>444</volume><fpage>295</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/nature05402</pub-id><pub-id pub-id-type="pmid">17108953</pub-id></element-citation></ref><ref id="B201-cancers-16-01191"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>Y.</given-names></name></person-group><article-title>Pond Assay for the Sensory Systems of Caenorhabditis Elegans: A Novel Anesthesia-Free Method Enabling Detection of Responses to Extremely Low Chemical Concentrations</article-title><source>Biology</source><year>2022</year><volume>11</volume><elocation-id>335</elocation-id><pub-id pub-id-type="doi">10.3390/biology11020335</pub-id><pub-id pub-id-type="pmid">35205201</pub-id><pub-id pub-id-type="pmcid">PMC8868598</pub-id></element-citation></ref><ref id="B202-cancers-16-01191"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirotsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sonoda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uozumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shinden</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mimori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maehara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hamakawa</surname><given-names>M.</given-names></name></person-group><article-title>A Highly Accurate Inclusive Cancer Screening Test Using Caenorhabditis Elegans Scent Detection</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0118699</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0118699</pub-id><pub-id pub-id-type="pmid">25760772</pub-id><pub-id pub-id-type="pmcid">PMC4356513</pub-id></element-citation></ref><ref id="B203-cancers-16-01191"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bargmann</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Hartwieg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Horvitz</surname><given-names>H.R.</given-names></name></person-group><article-title>Odorant-Selective Genes and Neurons Mediate Olfaction in C. Elegans</article-title><source>Cell</source><year>1993</year><volume>74</volume><fpage>515</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)80053-H</pub-id><pub-id pub-id-type="pmid">8348618</pub-id></element-citation></ref><ref id="B204-cancers-16-01191"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E.K.W.</given-names></name><name name-style="western"><surname>Martin-Alonso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Fadel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Jacks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>S.N.</given-names></name></person-group><article-title>Inhalable Point-of-Care Urinary Diagnostic Platform</article-title><source>Sci. Adv.</source><year>2024</year><volume>10</volume><fpage>eadj9591</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adj9591</pub-id><pub-id pub-id-type="pmid">38181080</pub-id><pub-id pub-id-type="pmcid">PMC10776015</pub-id></element-citation></ref><ref id="B205-cancers-16-01191"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubbell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Aravanis</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>C.D.</given-names></name></person-group><article-title>Modeled Reductions in Late-Stage Cancer with a Multi-Cancer Early Detection Test</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2021</year><volume>30</volume><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-1134</pub-id><pub-id pub-id-type="pmid">33328254</pub-id></element-citation></ref><ref id="B206-cancers-16-01191"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brill</surname><given-names>J.V.</given-names></name></person-group><article-title>Screening for Cancer: The Economic, Medical, and Psychosocial Issues</article-title><source>Am. J. Manag. Care</source><year>2020</year><volume>26</volume><issue>(Suppl. S14)</issue><fpage>S300</fpage><lpage>S306</lpage><pub-id pub-id-type="pmid">33200894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.37765/ajmc.2020.88534</pub-id></element-citation></ref><ref id="B207-cancers-16-01191"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tafazzoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Shaul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chavan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kansal</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Ofman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fendrick</surname><given-names>A.M.</given-names></name></person-group><article-title>The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA</article-title><source>Pharm. Econ.</source><year>2022</year><volume>40</volume><fpage>1107</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1007/s40273-022-01181-3</pub-id><pub-id pub-id-type="pmcid">PMC9550746</pub-id><pub-id pub-id-type="pmid">36038710</pub-id></element-citation></ref><ref id="B208-cancers-16-01191"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomczak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Czerwi&#324;ska</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wiznerowicz</surname><given-names>M.</given-names></name></person-group><article-title>The Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge</article-title><source>Contemp. Oncol.</source><year>2015</year><volume>19</volume><fpage>A68</fpage><lpage>A77</lpage><pub-id pub-id-type="doi">10.5114/wo.2014.47136</pub-id><pub-id pub-id-type="pmid">25691825</pub-id><pub-id pub-id-type="pmcid">PMC4322527</pub-id></element-citation></ref><ref id="B209-cancers-16-01191"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>B.</given-names></name><name name-style="western"><surname>Swatloski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ellrott</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cline</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diekhans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilks</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haussler</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The UCSC Cancer Genomics Browser: Update 2013</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>D949</fpage><lpage>D954</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1008</pub-id><pub-id pub-id-type="pmid">23109555</pub-id><pub-id pub-id-type="pmcid">PMC3531186</pub-id></element-citation></ref><ref id="B210-cancers-16-01191"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerami</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dogrusoz</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Sumer</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Aksoy</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Heuer</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data</article-title><source>Cancer Discov.</source><year>2012</year><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id><pub-id pub-id-type="pmcid">PMC3956037</pub-id></element-citation></ref><ref id="B211-cancers-16-01191"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrashekar</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Bashel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Balasubramanya</surname><given-names>S.A.H.</given-names></name><name name-style="western"><surname>Creighton</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ponce-Rodriguez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chakravarthi</surname><given-names>B.V.S.K.</given-names></name><name name-style="western"><surname>Varambally</surname><given-names>S.</given-names></name></person-group><article-title>UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses</article-title><source>Neoplasia</source><year>2017</year><volume>19</volume><fpage>649</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2017.05.002</pub-id><pub-id pub-id-type="pmid">28732212</pub-id><pub-id pub-id-type="pmcid">PMC5516091</pub-id></element-citation></ref><ref id="B212-cancers-16-01191"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab><name name-style="western"><surname>Weinstein</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Collisson</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>K.R.M.</given-names></name><name name-style="western"><surname>Ozenberger</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Ellrott</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shmulevich</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.M.</given-names></name></person-group><article-title>The Cancer Genome Atlas Pan-Cancer Analysis Project</article-title><source>Nat. Genet.</source><year>2013</year><volume>45</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/ng.2764</pub-id><pub-id pub-id-type="pmid">24071849</pub-id><pub-id pub-id-type="pmcid">PMC3919969</pub-id></element-citation></ref><ref id="B213-cancers-16-01191"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GTEx Consortium Human Genomics</collab></person-group><article-title>The Genotype-Tissue Expression (GTEx) Pilot Analysis: Multitissue Gene Regulation in Humans</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1126/science.1262110</pub-id><pub-id pub-id-type="pmid">25954001</pub-id><pub-id pub-id-type="pmcid">PMC4547484</pub-id></element-citation></ref><ref id="B214-cancers-16-01191"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>T.</given-names></name><name name-style="western"><surname>Troup</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Wilhite</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Ledoux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rudnev</surname><given-names>D.</given-names></name><name name-style="western"><surname>Evangelista</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Soboleva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tomashevsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edgar</surname><given-names>R.</given-names></name></person-group><article-title>NCBI GEO: Mining Tens of Millions of Expression Profiles&#8212;Database and Tools Update</article-title><source>Nucleic Acids Res.</source><year>2007</year><volume>35</volume><fpage>D760</fpage><lpage>D765</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl887</pub-id><pub-id pub-id-type="pmid">17099226</pub-id><pub-id pub-id-type="pmcid">PMC1669752</pub-id></element-citation></ref><ref id="B215-cancers-16-01191"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manoochehri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Giese</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Strobel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kutschmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hoheisel</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Moskalev</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Hackert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>A.S.</given-names></name></person-group><article-title>SST Gene Hypermethylation Acts as a Pan-Cancer Marker for Pancreatic Ductal Adenocarcinoma and Multiple Other Tumors: Toward Its Use for Blood-Based Diagnosis</article-title><source>Mol. Oncol.</source><year>2020</year><volume>14</volume><fpage>1252</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12684</pub-id><pub-id pub-id-type="pmid">32243066</pub-id><pub-id pub-id-type="pmcid">PMC7266283</pub-id></element-citation></ref><ref id="B216-cancers-16-01191"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name></person-group><article-title>Transcriptomic Analysis Reveals That Heat Shock Protein 90&#945; Is a Potential Diagnostic and Prognostic Biomarker for Cancer</article-title><source>Eur. J. Cancer Prev.</source><year>2020</year><volume>29</volume><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1097/CEJ.0000000000000549</pub-id><pub-id pub-id-type="pmid">31567483</pub-id></element-citation></ref><ref id="B217-cancers-16-01191"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.C.</given-names></name></person-group><article-title>DNA Methylation Markers for Pan-Cancer Prediction by Deep Learning</article-title><source>Genes</source><year>2019</year><volume>10</volume><elocation-id>778</elocation-id><pub-id pub-id-type="doi">10.3390/genes10100778</pub-id><pub-id pub-id-type="pmid">31590287</pub-id><pub-id pub-id-type="pmcid">PMC6826785</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="cancers-16-01191-f001" orientation="portrait"><label>Figure 1</label><caption><p>Comparison between the present concept of screening versus multi-cancer early detection screening. Inspired by Ahlquist et. al, and redesigned [<xref rid="B17-cancers-16-01191" ref-type="bibr">17</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancers-16-01191-g001.jpg"/></fig><table-wrap position="float" id="cancers-16-01191-t001" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01191-t001_Table 1</object-id><label>Table 1</label><caption><p>Differences in screening recommendations and adherence for the United States and the United Kingdom, with data regarding adherence, sensitivity, and specificity (data from Supplementary Table S1 from Hackshaw et al. [<xref rid="B19-cancers-16-01191" ref-type="bibr">19</xref>]).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cancer</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Screening Procedure</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Screening Interval</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">% Eligible Adults</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Adherence</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sensitivity</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Specificity</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" rowspan="1" colspan="1">Low-dose computed tomography</td><td align="center" valign="middle" rowspan="1" colspan="1">No Recommendation</td><td align="center" valign="middle" rowspan="1" colspan="1">Annually</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">14.4%</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">84.9%</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">87.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cologuard</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">FIT</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Every 3 years</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Every 2 years</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">93%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">68%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">67.7%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">57.7%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">92%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">79%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">87%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">94%</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Breast</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Bilateral mammography</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Annually</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Every 3 years</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">90% of women</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">77% of women</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">77.6%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">70.5%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">87%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">87%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">89%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">97.2%</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cervical</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Cytological examination and hrHPV testing</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Every 5 years</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Every 5 years</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">63% of women</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">60% of women</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95%</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">76.2%</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95%</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95%</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">85%</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">85%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-16-01191-t002" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01191-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparison between colon cancer screening recommendations for the average-risk population in different high-income countries (inspired by Ebell et al. [<xref rid="B29-cancers-16-01191" ref-type="bibr">29</xref>], and updated).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organization</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Eligible Population</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relevant Literature</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">United States</td><td align="center" valign="middle" rowspan="1" colspan="1">USPSTF</td><td align="center" valign="middle" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" rowspan="1" colspan="1">Shared decision-making between clinician and patient for one of the following strategies:<list list-type="simple"><list-item><label>-</label><p>g-FOBT/FIT every year.</p></list-item><list-item><label>-</label><p>Stool DNA-FIT every 1&#8211;3 years.</p></list-item><list-item><label>-</label><p>CT colonography every 5 years.</p></list-item><list-item><label>-</label><p>Flexible sigmoidoscopy every 5 years.</p></list-item><list-item><label>-</label><p>Flexible sigmoidoscopy every 10 years and annual FIT.</p></list-item><list-item><label>-</label><p>Colonoscopy screening every 10 years.</p></list-item></list></td><td align="center" valign="middle" rowspan="1" colspan="1">All adults aged 45&#8211;75 years; selectively screen adults aged 76&#8211;85 years</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B27-cancers-16-01191" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ACS</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>g-FOBT/FIT every year.</p></list-item><list-item><label>-</label><p>Stool DNA-FIT every 3 years.</p></list-item><list-item><label>-</label><p>Colonoscopy every 10 years</p></list-item><list-item><label>-</label><p>CT colonography every 5 years.</p></list-item><list-item><label>-</label><p>Flexible sigmoidoscopy every 5 years.</p></list-item></list>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 45&#8211;75; selectively screen adults aged 76&#8211;85 years</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-cancers-16-01191" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Luxembourg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ministry of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults between 55&#8211;74 years old invited to participate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Switzerland</td><td align="center" valign="middle" rowspan="1" colspan="1">League Against Cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" rowspan="1" colspan="1">2013</td><td align="left" valign="middle" rowspan="1" colspan="1">Colonoscopy every 10 years&#8212;g-FOBT every two years.</td><td align="center" valign="middle" rowspan="1" colspan="1">All adults aged 50&#8211;69</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B30-cancers-16-01191" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cancer Registry of Norway</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2022</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">FIT every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">All adults aged 55&#8211;74</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B31-cancers-16-01191" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NIPHE</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FIT every 2 years.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 55&#8211;75</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-cancers-16-01191" ref-type="bibr">32</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Germany</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Federal Joint Committee</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">National Guideline Committee</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2019</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women, 50&#8211;54: annual FIT.<break/>Women &gt;55: FIT every 2 years or colonoscopy twice at an interval of 10 years.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">All adults from 55 years onwards</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B33-cancers-16-01191" ref-type="bibr">33</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Men, 50&#8211;54: annual FIT or colonoscopy twice at an interval of 10 years.<break/>Men, &gt;55: FIT once every 2 years or colonoscopy twice at intervals of 10 years.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sweden</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Board of Health and Welfare</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 60&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-cancers-16-01191" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ireland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Screening Service</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bowel Screen Programme: FIT once every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 59&#8211;69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-cancers-16-01191" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Austria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Austrian Cancer Care</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colonoscopy every 10 years, or FIT every 2 years.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults 45&#8211;75 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-cancers-16-01191" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Board of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 50&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-cancers-16-01191" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Belgium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foundation Against Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 50&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-cancers-16-01191" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTFPHC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;59: g-FOBT/FIT every 2 years or flexible sigmoidoscopy every 10 years (weak recommendation).<break/>60&#8211;74 years: g-FOBT/FIT every 2 years or flexible sigmoidoscopy every 10 years (strong recommendation).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 50&#8211;74 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-cancers-16-01191" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australian Government Department of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 50&#8211;74 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-cancers-16-01191" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Institute</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years. Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 50&#8211;74 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-cancers-16-01191" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Center</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">g-FOBT once per year.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 40 and over</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-cancers-16-01191" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iceland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Icelandic Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years.<break/>Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 60&#8211;69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK National Screening Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years.<break/>Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All adults aged 50&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-cancers-16-01191" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Finland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society of Finland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years.<break/>Colonoscopy if positive test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults aged 56&#8211;74 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ministry of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time to Screen program offering FIT once every 2 years. Colonoscopy if the test is positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults aged 60&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-cancers-16-01191" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Italy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Screening Observatory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years. Colonoscopy if the test is positive.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults aged 50&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-cancers-16-01191" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Strategy of National Health System</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FIT once every 2 years.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults aged 50&#8211;69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-cancers-16-01191" ref-type="bibr">46</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CTFPHC = Canadian Task Force on Preventive Health Care; NA = Not available; NIPHE = National Institute for Public Health and the Environment, USPSTF = United Stated Preventive Services Task Force.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cancers-16-01191-t003" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01191-t003_Table 3</object-id><label>Table 3</label><caption><p>Comparison between breast cancer screening recommendations in different high-income countries (inspired by Ebell et al. [<xref rid="B29-cancers-16-01191" ref-type="bibr">29</xref>], and updated).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organization</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Further Discussion</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relevant Literature</th></tr></thead><tbody><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">United States</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">USPSTF</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">National Guideline Committee</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2023 *</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Women aged 40&#8211;75: biennial screening mammography</td><td align="center" valign="middle" rowspan="1" colspan="1">Insufficient evidence for mammography screening in women &gt;75</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B53-cancers-16-01191" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Insufficient evidence for breast US, or MRI in women identified with dense breasts on an otherwise negative screening mammogram</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015, 2007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women with average risk of breast cancer:<break/>ages 40&#8211;45&#8212;option to start yearly mammography<break/>ages 45&#8211;54&#8212;yearly mammography;<break/>ages &#8805;55&#8212;biennial/annual screening;<break/>continue mammography until life expectancy &#8805;10 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annual breast MRI screening in higher-risk patients: BRCA mutation, a first-degree relative of BRCA carrier (untested), the lifetime risk of &#8805;20&#8211;25% (as defined by BRCAPRO/other models), radiation to the chest between 10&#8211;30 years, Li&#8211;Fraumeni/Cowden/Bannayan&#8211;Riley&#8211;-Ruvalcaba syndrome and first-degree relatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-cancers-16-01191" ref-type="bibr">52</xref>,<xref rid="B54-cancers-16-01191" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACOG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specialty Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017, reaffirmed 2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Offer mammography starting at 40 years. Initiate at ages 40&#8211;49 years after counseling. Recommend by no later than age 50 if the patient has not already been initiated. Continue until age 75. Beyond 75, consider life expectancy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annual or biennial screening. Clinical breast examination may be offered for women aged 25&#8211;39 years and annually for women 40 years and older.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-cancers-16-01191" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specialty Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023, 2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk assessment by age 25. Annual mammography starting at the age of 40. Screening should continue past age 74 unless severe comorbidities limit life expectancy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women with genetically based increased risk, or with a calculated lifetime risk of &#8805;20% are recommended to undergo breast MRI surveillance starting at ages 25&#8211;30 and annual mammography starting between ages 25&#8211;40, depending on the risk.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-cancers-16-01191" ref-type="bibr">56</xref>,<xref rid="B57-cancers-16-01191" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Luxembourg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ministry of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Programme Mammographie targets women aged 50&#8211;70, inviting them for mammography every 23 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Switzerland</td><td align="center" valign="middle" rowspan="1" colspan="1">Swiss Cancer League</td><td align="center" valign="middle" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" rowspan="1" colspan="1">2016</td><td align="center" valign="middle" rowspan="1" colspan="1">Mammography once every 2 years for women aged 50&#8211;70 (74 in some cantons)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B58-cancers-16-01191" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cancer Registry of Norway</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women 50&#8211;69 years of age</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B59-cancers-16-01191" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NIPHE</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women 50&#8211;74 years of age</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-cancers-16-01191" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Federal Joint Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women 50&#8211;69 years of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-cancers-16-01191" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sweden</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Board of Health and Welfare</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women 40&#8211;74 years of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-cancers-16-01191" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ireland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Screening Service</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BreastCheck program offers mammography once every 2 years for all women aged 50&#8211;69 years.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-cancers-16-01191" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Austria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Austrian Cancer Aid Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women aged 45&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-cancers-16-01191" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Board of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women aged 50&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-cancers-16-01191" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Belgium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foundation Against Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women aged 50&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-cancers-16-01191" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTFPHC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2&#8211;3 years for participants aged 50&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For women aged 40&#8211;49 years, recommendation against mammography (shared decision-making with healthcare provider)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-cancers-16-01191" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australian Government Department of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BreastScreen program offers mammography every 2 years for women aged 50&#8211;74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program available for women from age 40, with mammography every 2 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-cancers-16-01191" ref-type="bibr">68</xref>,<xref rid="B69-cancers-16-01191" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Institute</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015, 2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for participants aged 50&#8211;74. Screening also includes manual breast exam</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yearly MRI, mammography, and US for patients from the age of 30 onwards in high-risk cases (genetic factor, family history, personal history of radiation treatments)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-cancers-16-01191" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Center</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every two years to women aged 40&#8211;69 &#177; manual breast examination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-cancers-16-01191" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iceland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Icelandic Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women aged 40&#8211;69 years. Invitation for women aged 70&#8211;74 to have mammography every three years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-cancers-16-01191" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK National Screening Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 3 years form women aged 50&#8211;70 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-cancers-16-01191" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Finland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society of Finland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women aged 50&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-cancers-16-01191" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ministry of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BreastScreen Aotearoa program offers mammography every two years for women aged 45&#8211;69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-cancers-16-01191" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Italy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Screening Observatory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women aged 50&#8211;69 years (45&#8211;69 in Campania region)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-cancers-16-01191" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Strategy of National Health System</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mammography once every 2 years for women aged 50&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-cancers-16-01191" ref-type="bibr">76</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* Currently a draft recommendation at the time of writing (March 2024). Abbreviations: ACOG = American College of Obstetrics and Gynecology, ACR = American College of Radiology; ACS = American Cancer Society; CTFPHC = Canadian Task Force on Preventive Health Care; NA = Not Available; NIPHE = National Institute for Public Health and the Environment, USPSTF = United Stated Preventive Services Task Force.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cancers-16-01191-t004" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01191-t004_Table 4</object-id><label>Table 4</label><caption><p>Comparison between cervical cancer screening recommendations in different high-income countries (inspired by Ebell et al. [<xref rid="B29-cancers-16-01191" ref-type="bibr">29</xref>], and updated).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organization</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Screening Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Eligible Population</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relevant Literature</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">United States</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USPSTF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 21&#8211;29: cytology alone every 3 years<break/>Women aged 30&#8211;65 years: cytology alone every 3 years, with HR-HPV testing alone every 5 years, or co-testing every 5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women between years 21&#8211;65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-cancers-16-01191" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Screen with HR-HPV testing every 5 years<break/>If not available, co-testing every 5 years, or cytology every 3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women between years 25&#8211;65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-cancers-16-01191" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACOG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specialty Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endorses USPSTF recommendations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women between years 21&#8211;65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-cancers-16-01191" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Luxembourg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ministry of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Switzerland</td><td align="center" valign="middle" rowspan="1" colspan="1">League Against Cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" rowspan="1" colspan="1">Women aged 21&#8211;29: cytological screening<break/>Women aged 30&#8211;70 years: cytological/HR-HPV screening every 3 years</td><td align="center" valign="middle" rowspan="1" colspan="1">Women between years 21&#8211;70</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B93-cancers-16-01191" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cancer Registry of Norway</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Cytology screening from the age of 25, HR-HPV testing from the age of 34</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;69 years</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B94-cancers-16-01191" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NIPHE</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HR-HPV screening every five years between 30&#8211;60 years</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Women aged 30&#8211;60</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-cancers-16-01191" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Germany</td><td align="center" valign="middle" rowspan="1" colspan="1">Federal Joint Committee</td><td align="center" valign="middle" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" rowspan="1" colspan="1">Women aged 21&#8211;35: annual genital examination, medical history, cytology<break/>Women aged &gt;35 are offered HR-HPV and cytology co-testing</td><td align="center" valign="middle" rowspan="1" colspan="1">Women aged 20</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B95-cancers-16-01191" ref-type="bibr">95</xref>,<xref rid="B96-cancers-16-01191" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sweden</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">National Board of Health and Welfare</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Women aged 23&#8211;29: Cytology-based screening once every three years<break/>Women aged 30&#8211;49: HR-HPV testing every three years with a cytology co-test at age 41<break/>Women aged 50&#8211;64: HR-HPV test every seven years</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Women aged 23&#8211;64</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-cancers-16-01191" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ireland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Screening Service</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CervicalCheck program&#8212;women aged 25&#8211;29 years: cervical screening every 3 years<break/>Women aged 30&#8211;65 years: cervical screening every 5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women between 25&#8211;65 years of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-cancers-16-01191" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Austria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Austrian Cancer Care</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytology every 3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women between 19&#8211;69 years of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-cancers-16-01191" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Board of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 23&#8211;49 years: co-testing every 3 years<break/>Women aged 50&#8211;64 years: co-testing every 5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women between 23&#8211;64 years of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-cancers-16-01191" ref-type="bibr">100</xref>,<xref rid="B101-cancers-16-01191" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Belgium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foundation Against Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytology tests every 3 years<break/>Women aged 30&#8211;64 years&#8212;HR-HPV test every five years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged between 25&#8211;64 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-cancers-16-01191" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTFPHC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytology every 3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged between 25&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-cancers-16-01191" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australian Government Department of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR-HPV testing every 5 years with cytology for positive tests</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;74 years of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-cancers-16-01191" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Institute</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women 25&#8211;30 years: cytology testing every 3 years<break/>Women 30&#8211;65 years HR-HPV testing every 5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;65 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-cancers-16-01191" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Center</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 20&#8211;69 years: cytology testing once every 2 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 20&#8211;69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-cancers-16-01191" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iceland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Icelandic Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 23&#8211;29 years: HR-HPV every three years<break/>Women aged 30&#8211;59 years: HR-HPV every five years<break/>Women aged 60&#8211;64 years: HR-HPV test&#8212;if a test is negative, women are discharged from screening</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 23&#8211;64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK National Screening Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR-HPV test once every 3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-cancers-16-01191" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Finland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society of Finland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytology once every five years (can be substituted with HR-HPV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-cancers-16-01191" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ministry of Health</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Society</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR-HPV once every five years (once every 3 years if immunodeficient) screening extended to women aged 70&#8211;74 years if unscreened or under-screened</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-cancers-16-01191" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Italy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Screening Observatory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;30 years: Cytology test once every three years<break/>Women aged 30&#8211;65 years: HPV-based screening every five years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;65 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-cancers-16-01191" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Strategy of National Health System</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Guideline Committee</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;34 years: cytology co-testing once every 3 years<break/>Women aged 35&#8211;65 years: HR-HPV testing every five years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women aged 25&#8211;65 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-cancers-16-01191" ref-type="bibr">109</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ACOG = American College of Obstetricians and Gynecologists; ACS = American Cancer Society; CTFPHC = Canadian Task Force on Preventive Health Care; NA = Not Available; NIPHE = National Institute for Public Health and the Environment.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cancers-16-01191-t007" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01191-t007_Table 7</object-id><label>Table 7</label><caption><p>Estimates of screening outcomes for the UK, per year, from Hackshaw et al. [<xref rid="B19-cancers-16-01191" ref-type="bibr">19</xref>] with permission from the authors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Current Screening Only</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Incremental MCED Test</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Positives</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">True Positive Cancers (Diagnostic Yield per 1000)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">True Positive/False Positive Ration</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Detection Rate</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic cost per Confirmed Cancer Diagnosis</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Positives</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic Yield per 1000</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">True Positive/False Positive Ration</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer Detection Rate</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic Cost per Confirmed Cancer Diagnosis</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% MCED uptake</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">481,876</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24,888 (3.43)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,452</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">244,153</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92,817 (4.26)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2175</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20% decrease cancer incidence in screening population</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">476,899</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19,910 (2.74)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,921</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246,220</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94,884 (4.35)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2134</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;4977</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;4978</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2469</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2067</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2067</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;41</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate cancer added</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">635,797</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,754 (2.61%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,917</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">243,586</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92,250 (4.23%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2187</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">153,921</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2866</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2465</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;567</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;567</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50% MCED uptake</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">122,076</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46,409 (4.23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2175</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;122,077</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;46,408</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25% MCED uptake</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61,038</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23,204 (4.23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2175</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;183,115</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;69,613</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30% decline in standard-of-care screening, only receiving MCED test</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76,346</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30,945 (4.72)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1989</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Difference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;167,807</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;61,872</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;186</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>